0001376339-17-000138.txt : 20171031 0001376339-17-000138.hdr.sgml : 20171031 20171031171546 ACCESSION NUMBER: 0001376339-17-000138 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171031 DATE AS OF CHANGE: 20171031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 171166553 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-Q 1 mdxg-2017930x10xq.htm 10-Q Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2017
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________________to______________________

Commission file number 001-35887
MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)
Florida
 
26-2792552
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification Number)
1775 West Oak Commons Ct. NE
Marietta, GA
 
30062
(Address of principal executive offices)
 
(Zip Code)
(770) 651-9100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
(Do not check if a smaller reporting company)
Smaller reporting company ¨
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(A) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x
 
As of October 13, 2017, there were 111,034,873 shares of the registrant’s common stock outstanding.



Table of Contents
 
Part I     FINANCIAL INFORMATION
 
Item 1
Condensed Consolidated Financial Statements
 
 
Condensed Consolidated Balance Sheets (unaudited) September 30, 2017 and December 31, 2016

 
Condensed Consolidated Statements of Operations (unaudited) Three and Nine Months Ended September 30, 2017 and 2016

 
Condensed Consolidated Statement of Stockholders' Equity (unaudited) for Nine Months Ended September 30, 2017

 
Condensed Consolidated Statements of Cash Flows (unaudited) Nine Months Ended September 30, 2017 and 2016

 
Notes to the Unaudited Condensed Consolidated Financial Statements Three and Nine Months Ended September 30, 2017 and 2016
8

Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3
Quantitative and Qualitative Disclosures About Market Risk

Item 4
Controls and Procedures

Part II   OTHER INFORMATION
Item 1
Legal Proceedings

Item 1A
Risk Factors

Item 2
Unregistered Sales of Equity Securities and Use of Proceeds

Item 3
Defaults upon Senior Securities

Item 4
Mine Safety Disclosures

Item 5
Other Information

Item 6
Exhibits

Signatures
 


2


As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.
Important Cautionary Statement
This Quarterly Report on Form 10-Q includes forward-looking statements, including, among others, statements regarding future economic performance and financial condition, including future levels of amortization expense, and our management's plans and objectives. These statements also may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions.
Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such statements are based upon the current beliefs and expectations of management and on information currently available to management. They speak as of the date hereof, and we do not assume any obligation to update the statements made herein or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events.
We list certain of the factors that could cause actual results to differ materially from those described in the forward-looking statements in Part I, Item 1A., "Risk Factors" in our 2016 Annual Report on Form 10-K and also include risks discussed in this report and in other periodic reports that we file with the Securities and Exchange Commission ("SEC").



3



Part I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements

MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
September 30, 2017
(unaudited)
 
December 31, 2016
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
36,522

 
$
34,391

Accounts receivable, net
59,581

 
67,151

Inventory, net
10,419

 
17,814

Prepaid expenses
6,662

 
5,894

Other current assets
926

 
1,288

Total current assets
114,110

 
126,538

Property and equipment, net of accumulated depreciation
13,264

 
13,786

Goodwill
19,894

 
20,203

Intangible assets, net of accumulated amortization
10,377

 
23,268

Deferred tax asset, net
17,671

 
9,114

Other assets
3,391

 
354

Total assets
$
178,707

 
$
193,263

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
8,767

 
$
11,436

Accrued compensation
15,092

 
12,365

Accrued expenses
8,613

 
10,941

Current portion of earn out liability
—

 
8,740

Income taxes
2,329

 
5,768

Other current liabilities
358

 
1,482

Total current liabilities
35,159

 
50,732

Earn out liability
—

 
8,710

Other liabilities
1,076

 
821

Total liabilities
36,235

 
60,263

Commitments and contingencies (Note 12)


 


Stockholders' equity:
 
 
 
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
—

 
—

Common stock; $.001 par value; 150,000,000 shares authorized;
112,703,926 issued and 111,035,248 outstanding at September 30, 2017 and 110,212,547 issued and 109,862,787 outstanding at December 31, 2016
112

 
110

Additional paid-in capital
163,446

 
161,261

Treasury stock at cost:
1,668,678 shares at September 30, 2017 and 349,760 shares at December 31, 2016
(24,784
)
 
(2,216
)
Accumulated earnings (deficit)
3,698

 
(26,155
)
Total stockholders' equity
142,472

 
133,000

Total liabilities and stockholders' equity
$
178,707

 
$
193,263

See notes to condensed consolidated financial statements

4


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016

 
 
 
 
 
 
 
Net sales
$
84,573

 
$
64,429

 
$
233,592

 
$
175,139

Cost of sales
9,599

 
7,997

 
26,972

 
23,338

Gross margin
74,974

 
56,432

 
206,620

 
151,801

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development expenses
5,481

 
2,919

 
14,430

 
8,582

Selling, general and administrative expenses
60,233

 
48,179

 
168,498

 
131,599

Amortization of intangible assets
418

 
631

 
1,451

 
1,889

Operating income
8,842

 
4,703

 
22,241

 
9,731

 
 
 
 
 
 
 
 
Other income (expense)
 
 
 
 
 
 
 
Gain on divestiture
4,274

 
—

 
4,274

 
—

Interest expense, net
(43
)
 
(87
)
 
(337
)
 
(254
)
 
 
 
 
 
 
 
 
Income before income tax provision
13,073

 
4,616

 
26,178

 
9,477

Income tax provision (expense) benefit
4,384

 
(1,295
)
 
3,675

 
(2,984
)
 
 
 
 
 
 
 
 
Net income
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

 
 
 
 
 
 
 
 
Net income per common share - basic
$
0.16

 
$
0.03

 
$
0.28

 
$
0.06

 
 
 
 
 
 
 
 
Net income per common share - diluted
$
0.15

 
$
0.03

 
$
0.26

 
$
0.06

 
 
 
 
 
 
 
 
Weighted average shares outstanding - basic
106,871,436

 
105,991,990

 
106,469,278

 
105,927,890

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted
117,501,925

 
112,361,179

 
116,547,006

 
112,193,701

See notes to condensed consolidated financial statements

5



MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands, except share data)
(unaudited)



 
 
Common Stock Issued
Additional Paid - in
Treasury Stock
Accumulated
 
 
 
Shares
Amount
Capital
Shares
Amount
Earnings (Deficit)
Total
Balance December 31, 2016
 
110,212,547

$
110

$
161,261

349,760

$
(2,216
)
$
(26,155
)
$
133,000

Share-based compensation expense
 
—

—

15,232



—

15,232

Exercise of stock options
 
1,097,933

1

(2,697
)
(1,319,836
)
14,286

—

11,590

Issuance of restricted stock
 
1,393,446

1

(13,108
)
(1,630,093
)
13,107

—

—

Restricted stock shares canceled/forfeited
 
—

—

2,717

283,198

(2,717
)
—

—

Shares issued for services performed
 

—

41

(17,539
)
125

—

166

Share repurchase
 
—

—


3,644,327

(44,032
)
—

(44,032
)
Shares repurchased for tax withholding
 
—

—


358,861

(3,337
)
 
(3,337
)
Net income
 
—

—

—

—

—

29,853

29,853

Balance September 30, 2017
 
112,703,926

$
112

$
163,446

1,668,678

$
(24,784
)
$
3,698

$
142,472


See notes to condensed consolidated financial statements

6


MIMEDX GROUP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
 
Nine Months Ended September 30,
 
2017
 
2016
Cash flows from operating activities:
 
 
 
Net income
$
29,853

 
$
6,493

Adjustments to reconcile net income to net cash from operating activities:
 
 
 
Depreciation
3,074

 
2,394

Amortization of intangible assets
1,451

 
1,889

Amortization of inventory fair value step-up
203

 
1,471

Amortization of deferred financing costs
135

 
136

Impairment of intangible assets
357

 
—

Share-based compensation
15,232

 
13,826

Change in deferred income taxes
(8,557
)
 
(449
)
Gain on divestiture
(4,274
)
 
—

Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in:
 
 
 
  Accounts receivable
5,165

 
(7,671
)
  Inventory
3,738

 
(3,599
)
  Prepaid expenses
(792
)
 
(2,023
)
  Other assets
(402
)
 
286

  Accounts payable
478

 
(3,941
)
  Accrued compensation
2,873

 
(4,223
)
  Accrued expenses
(2,228
)
 
2,020

  Income taxes
(3,438
)
 
2,621

  Other liabilities
(794
)
 
(82
)
Net cash flows from operating activities
42,074

 
9,148

 
 
 
 
Cash flows from investing activities:
 
 
 
 Purchases of equipment
(3,998
)
 
(5,301
)
 Stability acquisition
—

 
(7,631
)
 Fixed maturity securities redemption
—

 
3,000

 Patent application costs
(144
)
 
(515
)
Net cash flows from investing activities
(4,142
)
 
(10,447
)
 
 
 
 
Cash flows from financing activities:
 
 
 
 Proceeds from exercise of stock options
11,590

 
2,548

 Share repurchase under repurchase plan
(44,032
)
 
(10,378
)
 Share repurchase for tax withholdings on vesting of restricted stock
(3,337
)
 
(892
)
 Deferred financing costs
—

 
(106
)
 Payments under capital lease obligations
(22
)
 
(21
)
Net cash flows from financing activities
(35,801
)
 
(8,849
)
 
 
 
 
Net change in cash
2,131

 
(10,148
)
 
 
 
 
Cash and cash equivalents, beginning of period
34,391

 
28,486

Cash and cash equivalents, end of period
$
36,522

 
$
18,338

See notes to condensed consolidated financial statements

7


MIMEDX GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016
1.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three and nine months ended September 30, 2017 and 2016, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2016, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 1, 2017. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® and EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; and Placental Collagen family with CollaFix® and AmnioFill® brands. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord and AmnioCord are derived from the umbilical cord; and CollaFix® is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair and is in development. (Our former Physio product is owned by our former subsidiary, Stability Biologics, LLC which we divested effective September 30, 2017). See Note 3, Divestiture of Stability Biologics, LLC, below.
2.
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2016, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Notes Receivable
The Company's notes receivable as of September 30, 2017 are included in Other Assets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories are valued at the lower of cost or market, using the first-in, first-out ("FIFO") method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for

8


inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S., and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our customers and stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, were historically made through a distributor relationship with AvKARE Inc., which is a veteran-owned General Services Administration Federal Supply Schedule contractor. The Company's agreement with AvKARE expired on June 30, 2017. Upon expiration of the agreement, the Company had an obligation to repurchase AvKARE’s remaining inventory within 90 days in accordance with the terms of the agreement. As of September 30, 2017, the Company has satisfied the repurchase obligation.
A portion of the Company’s revenue is generated from consignment inventory maintained at hospitals or physicians' offices. Significant terms of our consignment agreements state that title to the inventory remains with the Company until the product, which has been segregated by the consignee, is withdrawn and therefore purchased by the consignee. The consignee accepts all risk of loss and full responsibility for any product in the consignment inventory that may be opened, lost, stolen or damaged. The Company recognizes revenue when we are notified that product has been used or implanted.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements. These estimates have historically been materially consistent with actual results.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their creditworthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. 
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes, after the measurement period has expired, to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $144,000 of patent costs during the first nine months of 2017. The Company capitalized approximately $515,000 of patent costs during the first nine months of 2016.


9


Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued and Adopted Accounting Standards
The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. We are in the process of completing our procedures for adoption of the standard. We have identified one revenue stream from our contracts with customers: product sales. Based upon the results of our work to date we have elected the modified retrospective method as we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)." The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," which simplifies several aspects of the accounting for share-based payment award transactions including (a) income tax consequences; (b) classification of awards as either debt or equity liabilities; and (c) classification on the statement of cash flows.  The amendments are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods.  The Company has adopted this ASU as of January 1, 2017. The primary amendment impacting the Company's financial statements is the requirement for excess tax benefits or shortfalls on the exercise of share-based compensation awards to be presented in income tax expense in the Consolidated Statements of Income during the period the award is exercised as opposed to being recorded in additional paid-in capital on the Consolidated Balance Sheets.  The excess tax benefit or shortfall is calculated as the difference between the fair value of the award on the date of exercise and the fair value of the award used to measure the expense to be recognized over the service period.  Changes are required to be applied prospectively to all excess tax benefits and deficiencies resulting from the exercise of awards after the date of adoption. The ASU requires a "modified retrospective" approach application for excess tax benefits that were not previously recognized in situations where the tax deduction did not reduce current taxes payable. For the three-month period ended September 30, 2017, the Company recorded an income tax benefit of $1,510,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $4,205,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. As the end result is dependent on the future value of the Company's stock as well as the timing of employee exercises, the amount of future impact cannot be quantified at this time. The Company has elected to continue to estimate forfeitures expected to occur to determine the share-based compensation expense.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-04,"Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment." The update eliminates Step 2 from the goodwill impairment test. This ASU is effective for fiscal years beginning after December 15, 2019. The amendments in this update should be applied on a prospective basis. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.


10



3. Divestiture of Stability Biologics, LLC

On September 30, 2017, we completed the previously announced divestiture (the “Stability Divestiture”) of our wholly-owned subsidiary, Stability Biologics, LLC, a Georgia limited liability company (successor-in-interest to Stability Inc., a Florida corporation) (“Stability LLC”), pursuant to the Membership Interest Purchase Agreement (“Agreement”) by and among the Company, Stability LLC, each person that, as of January 13, 2016, was a stockholder (the “Stockholders”) of Stability Inc., a Florida corporation and a predecessor-in-interest to Stability LLC ("Stability, Inc."), and Brian Martin, as stockholder representative, the terms of which were previously disclosed in the Current Report on Form 8-K dated August 18, 2017.

A summary of the assets divested and consideration received follows (in thousands):
 
 
September 30,
 
 
2017
Assets divested
 
 
Trade receivables
 
$
2,405

Inventories
 
2,800

Prepaid expenses and other assets
 
1,610

Goodwill (a)
 
309

Intangible assets
 
11,857

Property and equipment, net of accumulated depreciation
1,446

Total assets divested
 
20,427

 
 
 
Liabilities divested
 
 
Accounts payable and accrued liabilities
 
3,487

Total liabilities divested
 
3,487

 
 
 
Total net assets divested
 
$
16,940

 
 
 
Transaction costs
 
$
400

 
 
 
Consideration received
 
 
Non-trade receivable
 
150

Note receivable
 
3,190

Intangible assets
 
630

Extinguishment of earn out liability
 
17,644

Total consideration received
 
$
21,614

 
 
 
Gain on sale
 
$
4,274


(a) In accordance with ASC 350-20-35-52 when a portion of a reporting unit is disposed of, goodwill associated with that business shall be included in the carrying amount of the business in determining the gain on disposal. In accordance with ASC 350-20-35-53, the amount of goodwill to be included in that carrying amount shall be based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. Based on an estimated approximate fair value of Stability LLC compared to the business retained, approximately $300,000 out of the total goodwill of $20.2 million residing in the reporting unit was included in the carrying amount of the business sold.
 
The total gain on the Stability Divestiture of $10,011,000 is comprised of a pretax book gain of $4,274,000 and an associated tax benefit of $5,737,000, which consists principally of the write off of deferred tax liabilities related to Stability LLC.
4. Inventories

11


Inventories consisted of the following items as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30, 2017
 
December 31, 2016
Raw materials
$
690

 
$
1,148

Work in process
5,164

 
6,677

Finished goods
5,554

 
10,817

 Inventory, gross
11,408

 
18,642

Reserve for obsolescence
(989
)
 
(828
)
 Inventory, net
$
10,419

 
$
17,814


5. Property and Equipment 
Property and equipment consisted of the following as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30,
2017
 
December 31,
2016
Leasehold improvements
$
3,116

 
$
3,274

Lab and clean room equipment
9,316

 
8,666

Furniture and office equipment
9,203

 
7,051

Construction in progress
2,583

 
3,300

   Property and equipment, gross
24,218

 
22,291

Less accumulated depreciation
(10,954
)
 
(8,505
)
   Property and equipment, net
$
13,264

 
$
13,786


Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $8,600 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. The interest rate for the lease is approximately 12% with a maturity date of January 2018.
Also included in net property and equipment is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Gross depreciation expense for the nine months ended September 30, 2017 and 2016, was approximately $3,074,000 and $2,394,000, respectively, and approximately $1,013,000 and $838,000 for the three months ended September 30, 2017 and 2016, respectively. For the three and nine months ended September 30, 2017 approximately $626,000 of accumulated depreciation expense and $2,000,000 in gross book value of property and equipment was eliminated in connection with the Stability Divestiture.











12



6.
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2017
 
December 31, 2016
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,009

 
$
1,399

Patents & Know-How (b) (c) (d)
19 years
 
8,712

 
14,839

Customer & Supplier Relationships (b) (d)
13 years
 
4,271

 
9,091

Tradenames & Trademarks (d)
indefinite
 
1,008

 
1,458

Non-compete agreements
4 years
 
120

 
830

In Process Research & Development (b)
various
 
25

 
25

Patents in Process (c)
various
 
1,742

 
2,618

Total
 
 
16,887

 
30,260

Less Accumulated amortization and impairment charges
 
 
(6,510
)
 
(6,992
)
Net
 
 
$
10,377

 
$
23,268

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of September 30, 2017, the license was fully amortized.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. For the nine months ended September 30, 2017, approximately $663,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.
(d)
On January 13, 2016, the Company acquired Stability, Inc. As a result, the Company recorded intangible assets for Patents & Know-How of $6,790,000, Customer & Supplier Relationships of $5,330,000, Non-compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.
On September 30, 2017, the Company completed the Stability Divestiture which resulted in the transfer of intangible assets acquired in 2016 and the acquisition of a Distribution Agreement valued at $510,000 and a Non-compete Agreement valued at $120,000.
Gross amortization expense for the nine months ended September 30, 2017 and 2016, was approximately $1,451,000 and $1,889,000, respectively, and $418,000 and $631,000 for the three months ended September 30, 2017 and 2016, respectively. For the three and nine months ended September 30, 2017, approximately $1,932,000 of accumulated amortization expense was eliminated in connection with the Stability Divestiture.

13


Expected future amortization of intangible assets as of September 30, 2017, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2017 (a)
$
237

2018
950

2019
950

2020
950

2021
942

Thereafter
5,340

 
$
9,369

(a) Estimated amortization expense for the year ending December 31, 2017, includes only amortization to be recorded after September 30, 2017.

7. Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. In September 2017, the expiration date of the credit agreement was extended to October 12, 2019. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. The obligations of the loan parties under the Credit Agreement and the other credit documents are secured by liens on and security interests in substantially all of the assets of each of the loan parties and a pledge of the equity interests of each subsidiary owned by a loan party, subject to certain customary exclusions. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the initial life of the facility. The Credit Agreement contains customary representations, warranties, covenants and events of default, including restrictions on certain payments of dividends by the Company. As of September 30, 2017, there were no outstanding revolving loans under the credit facility, and the Company was in compliance with all covenants under the Credit Agreement.


8. Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net income
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

Denominator for basic earnings per share - weighted average shares
106,871,436

 
105,991,990

 
106,469,278

 
105,927,890

Effect of dilutive securities: Stock options and restricted stock outstanding(a)
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
117,501,925

 
112,361,179

 
116,547,006

 
112,193,701

Income per common share - basic
$
0.16

 
$
0.03

 
$
0.28

 
$
0.06

Income per common share - diluted
$
0.15

 
$
0.03

 
$
0.26

 
$
0.06


14


(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Outstanding stock options
7,916,564

 
5,704,112

 
7,985,521

 
5,767,469

Restricted stock awards
2,713,925

 
665,077

 
2,092,207

 
498,342

 
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811


9. Equity
Stock Incentive Plans 

The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.

Stock Options
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2017
12,552,608

 
$
3.61

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(2,417,769
)
 
$
4.80

 
 
 
 
Unvested options forfeited
(25,839
)
 
$
6.54

 
 
 
 
Vested options expired
(68,991
)
 
$
5.79

 
 
 
 

Outstanding at September 30, 2017
10,040,009

 
$
3.30

 
4.60
 
$
86,178,050

Vested at September 30, 2017
9,976,636

 
$
3.26

 
4.59
 
$
86,042,771

Vested or expected to vest at September 30, 2017 (a)
10,043,166

 
$
3.30

 
4.60
 
$
86,176,954

(a)
Includes forfeiture-adjusted unvested shares.
The intrinsic value of the options exercised during the nine months ended September 30, 2017, was approximately $17,994,945. 

15


Following is a summary of stock options outstanding and exercisable at September 30, 2017:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.70 - $1.09
1,094,429

 
2.8
 
$
0.91

 
1,094,429

 
$
0.91

$1.10 - $1.65
4,290,379

 
3.7
 
1.30

 
4,290,379

 
1.30

$2.45 - $3.75
854,001

 
5.0
 
2.77

 
854,001

 
2.77

$4.19 - $6.38
1,989,205

 
5.7
 
5.36

 
1,989,205

 
5.36

$6.49 - $9.78
1,713,328

 
6.4
 
7.30

 
1,683,625

 
7.26

$9.90 - $10.99
98,667

 
7.2
 
10.38

 
64,997

 
10.38

 
10,040,009

 
4.6
 
$
3.30

 
9,976,636

 
$
3.26

 
Total unrecognized compensation expense related to granted stock options at September 30, 2017, was approximately $98,900 and will be charged to expense ratably through January 2018. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
There were no options granted during the nine months ended September 30, 2017 and September 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards for the nine months ended September 30, 2017 is summarized as follows and includes 17,539 shares of common stock valued at approximately $166,000 which were issued under the 2016 Plan to a consultant in return for services performed: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2017
3,828,445

 
$8.53
Granted
3,041,078

 
9.23
Vested
(1,457,449
)
 
8.42
Forfeited
(283,198
)
 
8.67

Unvested at September 30, 2017
5,128,876

 
8.97
As of September 30, 2017, there was approximately $32,910,620 of total unrecognized share-based compensation expense related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.04 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at September 30, 2017.
For the three and nine months ended September 30, 2017 and 2016, the Company recognized share-based compensation expense as follows (in thousands): 

16


 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Cost of sales
$
119

 
$
109

 
$
393

 
$
300

Research and development
148

 
159

 
425

 
520

Selling, general and administrative
5,039

 
4,433

 
14,414

 
13,006

 
$
5,306

 
$
4,701

 
$
15,232

 
$
13,826

Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. Our Board subsequently extended the program until December 31, 2017, and increased the total authorization to $120 million as of October 26, 2017. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the nine months ended September 30, 2017, the Company repurchased 3,644,327 shares of its common stock for a purchase price of approximately $43,923,000 before brokerage commissions of approximately $109,000. As of September 30, 2017, the Company had approximately $13,000 of availability remaining under the repurchase program. In addition, the Company repurchased 358,861 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock for the nine months ended September 30, 2017.
Additionally, for the nine months ended September 30, 2017, the Company reissued 2,684,270 shares from the treasury for restricted stock grants and stock option exercises, net of forfeitures, with an aggregate carrying value of approximately $24,801,000.
10. Income Taxes 

The effective tax rate for the three months ended September 30, 2017 was (33.5)% and reflects discrete tax benefits related to the Stability Divestiture of $5,737,000, and $1,702,000 primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was 15.4% for the three months ended September 30, 2017 and 28.1% for the three months ended September 30, 2016, respectively.
The effective tax rate for the nine months ended September 30, 2017 was (14.0)% and reflects discrete tax benefits related to the Stability Divestiture of $5,737,000, and $5,618,000 primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was 9.4% for the nine months ended September 30, 2017 and 31.5% for the nine months ended September 30, 2016, respectively.
As of the end of September 2017, the projected annual effective tax rate for 2017 is 35.1% (excluding discrete items).

11. Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2017
 
2016
Cash paid for interest
$
119

 
$
118

Income taxes paid
8,289

 
637

Share issuance of 441,009 shares in connection with acquisition
—

 
3,346

Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively
166

 
346


17


12. Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 5, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space.
The estimated annual lease payments, meeting space commitments are as follows (in thousands):
Twelve months ended September 30,
2018
$
2,634

2019
2,826

2020
1,707

2021
1,428

2022
1,470

Thereafter
495

 
$
10,560


Rent expense for the nine months ended September 30, 2017 and 2016, was approximately $1,244,000 and $1,311,000, respectively, and was approximately $403,000 and $453,000 for the three months ended September 30, 2017 and 2016, respectively, and is allocated among cost of sales, research and development and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $52,000.

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, the Company would need a biologics license to lawfully market those micronized products (the "Untitled Letter"). Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's micronized allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing human cells, tissues, and cellular and tissue-based products ("HCT/P") regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from the FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with current good manufacturing processes ("cGMP"). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to

18


market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products.

Former Employee Litigation

On December 13, 2016, the Company filed lawsuits against former employees Jess Kruchoski (in the lawsuit styled MiMedx Group, Inc. v. Academy Medical, LLC, et. al. in the County Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the “Florida Action”)) and Luke Tornquist (in the lawsuit styled MiMedx Group, Inc., v. Luke Tornquist in the Superior Court for Cobb County, Georgia, which was removed to the United States District Court for the Northern District of Georgia (the “Georgia Action”)).  Both the Florida and Georgia Actions assert claims against Messrs. Kruchoski and Tornquist that each of them violated their restrictive covenants entered into with the Company, that each of them misappropriated trade secrets of the Company, that each of them tortiously interfered with contracts between the Company and its customers and employees and that each of them breached his duty of loyalty owed to the Company, among other claims. The Company sought injunctive relief against each of Mr. Kruchoski and Tornquist to enforce its restrictive covenants in place with each of them. The Company obtained consent injunctions from each party enforcing those covenants. The Company is also seeking monetary damages in an amount to be determined at trial.

The Company continues to vigorously pursue its claims asserted in all of these actions and also to vigorously defend against the lawsuits and counterclaims asserted against it.

Patent Litigation

The Company continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. (formerly known as AFCell Medical, Inc.) ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of the Company's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached a settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

The Company asserts that Liventa, Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. Trial has been set for the week of January 22, 2018.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. On September 7, 2017, the Court granted partial summary judgment in defendants’ favor on a portion of the claim. The Company filed a motion for reconsideration on October 4, 2017.





19



The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "'494" patent). Vivex answered the Company’s complaint and filed counterclaims of non-infringement and invalidity. On January 4, 2017, the Court granted a joint motion to stay the proceedings pending the outcome of the Bone Bank Action.

IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review ("IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "'687" patent) and the '494 patent, while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. The Company decided not to appeal the decision, as it impacted a non-core patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.  The Company filed an appeal of the PTAB’s decision regarding the '437 patent. On September 14, 2017, the Federal Circuit affirmed the PTAB’s decision regarding the ‘437 patent.


Other Litigation

The Capitol Forum Litigation

On September 21, 2017, MiMedx filed a lawsuit against DBW Partners LLC d/b/a The Capitol Forum (the “Capitol Forum”), Trevor Baine, Teddy Downey, Jake Williams, Miles Pulsford, Matt Treacy and John Does 1-100 (collectively, the “Capitol Defendants”) in the United States District Court for the District of Columbia. The Company has brought claims for defamation, libel, slander, tortious interference, false light, and violations of the Lanham Act in relation to the Capitol Defendants publishing articles and sending emails to shareholders that are false and misleading for the purpose of negatively impacting the price of MiMedx stock. The Capitol Defendants have not yet responded to the Company’s complaint.

The Aurelius Value and Viceroy Litigation

On October 4, 2017, the Company and Sean McCormack (a Company employee) filed a lawsuit against Sparrow Fund Management LP a/k/a Aurelius Value, Viceroy Research, John Fichthorn, BR Dialectic Capital Management LLC and John Does 1-10 in the United States District Court for the Southern District of New York asserting claims for libel, slander,

20


defamation, false light and tortious interference based on false and misleading “research” reports and other false and misleading statements allegedly published in order to manipulate the Company's stock. Defendants Sparrow, Fichthorn, and BR Dialectic have filed motions to dismiss MiMedx’s complaint which are pending before the court.

21



Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Nine Months Ended September 30, 2017 and 2016 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended September 30, 2017
 
 
 
 
 
Allowance for doubtful accounts
 
$
7,219

$
150

$
(409
)
$
6,960

Allowance for sales returns, discounts and allowances
 
3,461

1,288

(1,270
)
3,479

Allowance for obsolescence
 
1,113

212

(336
)
989

 
 
 
 
 
 
For the three months ended September 30, 2016
 
 
 
 
 
Allowance for doubtful accounts
 
$
4,086

$
800

$
(536
)
$
4,350

Allowance for sales returns, discounts and allowances
 
2,191

2,591

(2,520
)
2,262

Allowance for obsolescence
 
1,780

339

(1,411
)
708

 
 
 
 
 
 
For the nine months ended September 30, 2017
 
 
 
 
 
Allowance for doubtful accounts
 
$
4,842

$
2,600

$
(482
)
$
6,960

Allowance for sales returns, discounts and allowances
 
4,894

5,794

(7,209
)
3,479

Allowance for obsolescence
 
828

953

(792
)
989

 
 
 
 
 
 
For the nine months ended September 30, 2016
 
 
 
 
 
Allowance for doubtful accounts
 
$
3,270

$
1,635

$
(555
)
$
4,350

Allowance for sales returns, discounts and allowances
 
1,262

5,917

(4,917
)
2,262

Allowance for obsolescence
 
397

1,910

(1,599
)
708



22


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® and EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; and Placental Collagen family with CollaFix® and AmnioFill® brands. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord and AmnioCord are derived from the umbilical cord; and CollaFix®, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair, is in development. (Our former Physio product is owned by our former subsidiary, Stability LLC which we divested effective September 30, 2017). See Note 3, Divestiture of Stability Biologics, LLC, above.







23


Results of Operations Comparison for the Three Months Ended September 30, 2017 to the Three Months Ended September 30, 2016
Revenue

We recorded revenue for the three months ended September 30, 2017 of $84.6 million, approximately a $20.1 million, or 31.3%, increase over the three months ended September 30, 2016 revenue of $64.4 million.

Wound Care revenue for the three months ended September 30, 2017 was $61.9 million, which represented a $12.1 million, or 24.3%, increase over the three months ended September 30, 2016 revenue of $49.8 million. Surgical, Sports Medicine & Orthopedics ("SSO") revenue for the three months ended September 30, 2017 was $22.7 million, which represented a $8.1 million, or 55.5%, increase over the three months ended September 30, 2016 revenue of $14.6 million.

The revenue increase of approximately $20.1 million for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016 includes approximately $26.0 million in volume from market share gains and market expansion. Overall pricing was $1.4 million more favorable, partially offsetting an unfavorable product mix of $7.3 million.
We group our products into two categories: Wound Care and SSO for purposes of the required disclosure under ASC 280-10-50-40. This grouping of products does not constitute a basis for resource allocation but is information intended to provide the reader with the ability to better understand our product categories. These groupings also do not meet the criteria under ASC 280-10-50-1 as a separate segment.
Gross Margin

Gross margins for the three months ended September 30, 2017 were 88.7% as compared to 87.6% for the three months ended September 30, 2016. Gross margins increased due to the impact of lower one-time inventory costs incurred in 2016 in connection with the Stability, Inc. acquisition as well as volume driven manufacturing efficiencies and yield improvement in our Wound Care and SSO product lines.
Research and Development Expenses 

Our research and development expenses increased approximately $2.6 million, or 87.8%, to $5.5 million for the three months ended September 30, 2017, compared to approximately $2.9 million for the three months ended September 30, 2016. The increase is primarily related to increased investments in clinical trials.

Selling, General and Administrative Expenses

Selling, General and Administrative ("SG&A") expenses for the three months ended September 30, 2017 increased approximately $12.0 million, or 24.9%, to $60.2 million compared to $48.2 million for the three months ended September 30, 2016. Selling expense increases were driven primarily by costs associated with the continued build out of our direct sales organization for both the Wound Care and SSO markets. Total sales and marketing head count was at 449 at September 30, 2017, an increase of 79 employees since September 30, 2016 with a significant portion of the additions dedicated to our direct sales activity. Related expense for sales commissions and travel were also higher due to sales volume and head count increases. General and administrative expense increases were driven primarily by costs associated with adding personnel to support and maintain continued growth including reimbursement staffs and other support areas. Total General and Administrative head count was at 160 at September 30, 2017 as compared to 122 at September 30, 2016. Litigation costs tied to general and patent litigation were at $3.5 million for the quarter as compared to $1.2 million in the prior year. Also included in SG&A were increased provisions for bonuses, increased share-based compensation and bank fees. Share-based compensation included in SG&A for the three months ended September 30, 2017 and 2016 was approximately $5.0 million and $4.4 million, respectively, an increase of approximately $0.6 million, or 13.6%.
Amortization of Intangible Assets
Amortization expense related to intangible assets decreased approximately $0.2 million, or 33.3%, to $0.4 million for the three months ended September 30, 2017, compared to $0.6 million in the three months ended September 30, 2016. Amortization decreased primarily due to the Stability Divestiture during the quarter with an increased reduction expected in the fourth quarter of 2017 where there will be a full quarterly impact. We amortize our intangible assets over a period of 4 to 19 years, which we

24


believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill, but we test our goodwill at least annually for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.
Income Taxes
The effective tax rate decreased approximately 61.6% when compared to the same period of 2016, primarily due to the tax benefit associated with the Stability Divestiture and large share-based compensation-related discrete income tax benefits recorded during the three months ended September 30, 2017. As of the end of September 2017, the projected annual effective tax rate for 2017 is 35.1%.

Results of Operations Comparison for the Nine Months Ended September 30, 2017 to the Nine Months Ended September 30, 2016
Revenue
We recorded revenue for the nine months ended September 30, 2017 of $233.6 million, a $58.5 million, or 33.4%, increase over the nine months ended September 30, 2016 revenue of $175.1 million.

Wound Care revenue for the nine months ended September 30, 2017 was $171.4 million, which represented approximately a $40.2 million, or 30.6%, increase over the nine months ended September 30, 2016 revenue of $131.2 million. SSO revenue for the nine months ended September 30, 2017 was $62.2 million, which represented approximately a $18.3 million, or 41.7%, increase over the nine months ended September 30, 2016 revenue of $43.9 million. The increase in revenue was driven by increased staffing, new product introductions and additional product reimbursements.

The revenue increase of $58.5 million for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016 includes approximately $70.9 million in volume from market share gains and market expansion, favorable pricing variances of $3.3 million, partially offset by unfavorable product mix variance of $15.7 million.
Gross Margin
Gross margins for the nine months ended September 30, 2017 were 88.5% as compared to 86.7% for the nine months ended September 30, 2016. Gross margins increased due to the impact of lower one-time inventory costs incurred in 2016 in connection with the Stability Inc. acquisition as well as volume driven manufacturing efficiencies and yield improvement in our Wound Care and SSO product lines.
Research and Development Expenses 
Our research and development expenses increased approximately $5.8 million, or 68.1%, to $14.4 million for the nine months ended September 30, 2017, compared to approximately $8.6 million for the nine months ended September 30, 2016. The increase is primarily related to increased investments in clinical trials, animal studies, lab expenses, patent costs and personnel costs.
Selling, General and Administrative Expenses
SG&A expenses for the nine months ended September 30, 2017 increased approximately $36.9 million, or 28.0%, to $168.5 million compared to $131.6 million for the nine months ended September 30, 2016. Selling expense increases were driven primarily by costs associated with the continued build out of our direct sales organization for both the Wound Care and SSO markets, as well as increased commissions due to higher sales volume. General and Administrative expense increases were driven primarily by costs associated with adding personnel to support and maintain the continued growth including reimbursement staffs and other support areas as well as bonus and share-based compensation expenses. In addition, litigation expense was up $4.1 million for the nine months ended September 30, 2017 as compared to the comparable prior year period. SG&A expenses consists of personnel cost, bonus accrual, professional fees, sales commission, sales training costs, industry trade show fees and expenses, product promotion and product literature costs, facility costs, and other sales, marketing and administrative costs, bad debt, depreciation and amortization, and share-based compensation. Share-based compensation included in SG&A for the nine months ended September 30, 2017 and 2016 was approximately $14.4 million and $13.0 million, respectively, an increase of approximately $1.4 million, or 10.8%.
Amortization of Intangible Assets
Amortization expense related to intangible assets decreased approximately $0.4 million, or 21.1%, to $1.5 million for the nine months ended September 30, 2017, compared to $1.9 million in the nine months ended September 30, 2016. Amortization decreased due to the Stability Divestiture during the quarter with an increased reduction expected in the fourth quarter of 2017 where there will be a full quarterly impact as well as lower amortization in 2017 related to the write down of the Stability LLC

25


intangibles in the fourth quarter of 2016. We amortize our intangible assets over a period of 4 to 19 years, which we believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill but we test our goodwill at least annually for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.
Income Taxes
The effective tax rate decreased approximately 45.5% when compared to the same period of 2016, primarily due to the tax benefit associated with the Stability Divestiture and large share-based compensation-related discrete income tax benefits recorded during the nine months ended September 30, 2017. As of the end of September 2017, the projected annual effective tax rate for 2017 is 35.1%.
Liquidity and Capital Resources
As of September 30, 2017, we had approximately $36.5 million of cash and cash equivalents. We reported total current assets of approximately $114.1 million and total current liabilities of approximately $35.2 million at September 30, 2017, which represents a current ratio of 3.2 as of September 30, 2017.

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement established a senior secured revolving credit facility in favor of the Company, with an aggregate lender commitment of up to $50 million. In September 2017, the expiration date of the Credit Agreement was extended to October 12, 2019. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million. As of September 30, 2017, we were in compliance with all of our covenants under the Credit Agreement.
For the nine months ended September 30, 2017, we repurchased 3,644,327 shares of its common stock for a purchase price of approximately $43,923,000, before brokerage commissions of approximately $109,000 bringing the total amount spent under the program to approximately $99,987,000 since inception in 2014. As of September 30, 2017, we had approximately $13,000 of availability remaining under the repurchase program. The timing and amount of future repurchases, if any, will depend upon stock price, economic and market conditions, regulatory requirements, and other corporate considerations. We may initiate, suspend or discontinue purchases under the stock repurchase program at any time. In October 2017, we announced that our Board of Directors had approved an increase of $20 million to our repurchase authorization, bringing the total authorization to $120 million.
In addition, during the nine months ended September 30, 2017, the Company repurchased 358,861 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.
We believe that our anticipated cash from operating activities, existing cash and cash equivalents, and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.
Contingencies
See Note 12 to our Condensed Consolidated Financial Statements in Part I, Item 1 herein.
Contractual Obligations
Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods.  The table below summarizes the amounts and estimated timing of these future cash payments as of September 30, 2017 (in thousands):

26


 
 
 
Less than
 
 
 
 
 
 
Contractual Obligations
TOTAL
 
1 year
 
1-3 years
 
3-5 years
 
Thereafter
Capital lease obligations
$
9

 
$
9

 
$
—

 
$
—

 
$
—

Operating lease obligations
8,316

 
1,552

 
3,371

 
2,898

 
495

Meeting space commitments
2,244

 
1,082

 
1,162

 
—

 
—

 
$
10,569

 
$
2,643

 
$
4,533

 
$
2,898

 
$
495

Discussion of cash flows
Net cash from operating activities during the nine months ended September 30, 2017 increased approximately $33.0 million to approximately $42.1 million, compared to $9.1 million from operating activities for the nine months ended September 30, 2016, primarily attributable to an increase in net income, as well as favorable changes in accounts receivable, inventory, accounts payable and accrued compensation, when compared to the prior year.
Net cash used in investing activities during the nine months ended September 30, 2017 was approximately $4.1 million, compared to approximately $10.4 million for the same period in 2016. Cash used in the nine months ended September 30, 2016 for the acquisition of Stability, Inc. totaled $7.6 million.
Net cash used in financing activities during the nine months ended September 30, 2017 increased approximately $27.0 million to $35.8 million compared to $8.8 million of cash used during the nine months ended September 30, 2016. Cash used in financing activities during the nine months ended September 30, 2017 included approximately $44.0 million for stock repurchases under the repurchase plan compared to $10.4 million in the same period in the prior year. Additionally, we received $11.6 million from the exercise of stock options in the nine months ended September 30, 2017 compared to approximately $2.5 million in the same period in the prior year.
Non-GAAP Financial Measures
In addition to our GAAP results, we provide certain Non-GAAP metrics including Adjusted EBITDA, Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per share. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies. Adjusted EBITDA consists of GAAP Net Income excluding: (i) depreciation and amortization, (ii) interest income and expense, (iii) income taxes, (iv) one time acquisition related costs, (v) the effect of purchase accounting due to acquisitions, (vi) share-based compensation expense and (vii) gain on divestiture. Beginning in 2016, we have reported Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per Share to normalize results for comparison purposes. Adjusted Gross Margin consists of GAAP gross margin excluding amortization of inventory fair value step-up. Adjusted Net Income and Adjusted Diluted Net Income per share consists of GAAP net income excluding: (i) one time acquisition related costs, (ii) amortization of inventory fair value step-up, (iii) amortization of intangible assets, (iv) share-based compensation and (v) gain on divestiture. Reconciliations of GAAP Net Income to Adjusted EBITDA, GAAP Gross Margin to Adjusted Gross Margin and GAAP Net Income to Adjusted Net Income and Adjusted Diluted Net Income per share for the three and nine months ended September 30, 2017 and 2016 appear in the tables below (in thousands).

27


Our Adjusted EBITDA for the three months ended September 30, 2017 was approximately $15.6 million which is an increase of $4.3 million as compared to the three months ended September 30, 2016. The increase was attributable to higher net income before taxes, partially offset by a lower add back for income taxes compared to the prior year. Our Adjusted EBITDA for the nine months ended September 30, 2017, was approximately $42.2 million which is an increase of $11.7 million as compared to the nine months ended September 30, 2016. The increase was attributable to higher net income before taxes, partially offset by the gain on divestiture, and income taxes compared to the prior year.
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net Income (Per GAAP)
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

 
 
 
 
 
 
 
 
Add back:
 
 
 
 
 

 
 

Gain on divestiture
(4,274
)
 
—

 
(4,274
)
 
—

Income tax expense (benefit)
(4,384
)
 
1,295

 
(3,675
)
 
2,984

One time costs incurred in connection with acquisition
—

 
237

 
—

 
1,088

One time inventory costs incurred in connection with acquisition
50

 
247

 
203

 
1,578

Other interest expense, net
43

 
87

 
337

 
254

Depreciation expense
1,013

 
838

 
3,074

 
2,394

Amortization of intangible assets
418

 
631

 
1,451

 
1,889

Share-based compensation
5,306

 
4,701

 
15,232

 
13,826

Adjusted EBITDA
$
15,629

 
$
11,357

 
$
42,201

 
$
30,506


Reconciliation of "Adjusted Gross Margin" defined as Gross Margin before Amortization of inventory fair value step-up (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Gross Margin (Per GAAP)
$
74,974

 
$
56,432

 
$
206,620

 
$
151,801

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 
 
 
 
 
One time inventory costs incurred in connection with acquisition
50

 
247

 
203

 
1,578

Gross Margin before Amortization of inventory fair value step-up
$
75,024

 
$
56,679

 
$
206,823

 
$
153,379

Adjusted Gross Margin
88.7
%
 
88.0
%
 
88.5
%
 
87.6
%

Reconciliation of "Adjusted Net Income" and "Adjusted Diluted Net Income" per share defined as Net Income less Amortization, One Time Costs, Share-Based Compensation and Gain on Divestiture (in thousands, except share and per share data):

28


 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net Income (Per GAAP)
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

 
 
 
 
 
 
 
 
Non-GAAP Adjustments:
 
 
 

 
 

 
 

Tax rate normalization*
(7,439
)
 
(539
)
 
(11,355
)
 
(901
)
Gain on divestiture
(4,274
)
 
—

 
(4,274
)
 
—

One time costs incurred in connection with acquisition
—

 
237

 
—

 
1,088

One time inventory costs incurred in connection with acquisition
50

 
247

 
203

 
1,578

Amortization of intangible assets
418

 
631

 
1,451

 
1,889

Share - based compensation
5,306

 
4,701

 
15,232

 
13,826

Estimated income tax impact from adjustments
(1,996
)
 
(2,384
)
 
(5,920
)
 
(7,686
)
Adjusted Net Income
$
9,522

 
$
6,214

 
$
25,190

 
$
16,287

Adjusted Diluted Net Income per Share
$
0.08

 
$
0.06

 
$
0.22

 
$
0.15

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
117,501,925

 
112,361,179

 
116,547,006

 
112,193,701

*Assumes a normalized tax rate of 41% for 2016 and 35.1% for 2017.
Critical Accounting Policies
In preparing financial statements, we follow accounting principles generally accepted in the United States, which require us to make certain estimates and apply judgments that affect our financial position and results of operations. Management continually reviews our accounting policies and financial information disclosures. A summary of significant accounting policies that require the use of estimates and judgments in preparing the financial statements was provided in our Annual Report on Form 10-K for the year ended December 31, 2016.  During the quarter covered by this report, there were no material changes to the accounting policies and assumptions previously disclosed, except as disclosed in Note 2 to the Condensed Consolidated Financial Statements contained herein.
Recent Accounting Pronouncements
For the effect of recent accounting pronouncements, see Note 2 to the Condensed Consolidated Financial Statements contained herein.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements.

29


Item 3. Quantitative and Qualitative Disclosures about Market Risk

Based on our lack of market risk sensitive instruments outstanding at September 30, 2017, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

30


Item 4. Controls and Procedures
Disclosure Controls and Procedures
We maintain “disclosure controls and procedures” within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the "Exchange Act." Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Our disclosure controls and procedures include controls and procedures designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As required by Rule 13a-15(b) of the Exchange Act, prior to filing this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, were not effective because of the material weakness in our internal control over financial reporting, as described in Management’s Report On Internal Control Over Financial Reporting in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2016 (the "2016 10-K"), which continues to exist as of September 30, 2017.

Remediation of Material Weakness in Internal Control over Financial Reporting

The Company took steps during the first nine months of 2017 to remediate its material weakness in internal control over financial reporting related to our accounting for income taxes.  In reviewing the Company's tax accounting in preparation for filing the 2016 10-K, management concluded the Company had a material weakness in the design of our internal control over the tax accounting related to an overstatement of an excess tax benefit which, if undetected could have resulted in an understatement of income taxes payable. Specifically, management did not have adequate supervision and review of certain technical tax accounting performed by a third party tax specialist in 2016.

The Company has made progress implementing activities and improvements to address the control deficiency that led to the material weakness during the first nine months of 2017 which include:

•
Implementing specific review procedures, including the increased involvement of our CFO and Controller.

•
Hiring of an internal tax specialist to oversee the work performed by the third party tax specialists.

•
Strengthening our income tax control with improved documentation standards, technical oversight, and training.

When fully implemented and operational, we believe the measures described above will remediate the material weakness we have identified and generally strengthen our internal control over financial reporting. The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.  Our goal is to remediate this material weakness by the end of the 2017 fiscal year, subject to there being sufficient opportunities to conclude, through testing, that the enhanced control is operating effectively.

Changes in Internal Control over Financial Reporting

Other than the efforts discussed immediately above in Remediation of Material Weakness in Internal Control over Financial Reporting, there was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2017, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

31


PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are a party to various legal claims and actions incidental to our business. We discuss these items more fully in in Part I, Item 1, Note 12 to our Condensed Consolidated Financial Statements, which we incorporate by reference herein.
Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

32


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Stock Repurchases 

The following table sets forth information regarding the purchases of the Company’s equity securities made by or on behalf of the Company or any affiliated purchaser (as defined in Exchange Act Rule 10b-18) during the three month period ended September 30, 2017:

 
Total number of
shares purchased (a)
 
Average price paid
per share
 
Total number of shares purchased under publicly announced plan(b)
 
Total amount spent under the plan
 
Remaining amount
to be spent
under the plan (b)
Total amount remaining July 1, 2017
 
 
 
 
 
 
 
 
$
15,242,818

 
 
 
 
 
 
 
 
 
 
July 2017 increased spending authorization
 
 
 
 
 
 
 
 
$
14,000,000

 
 
 
 
 
 
 
 
 
 
July 1, 2017 - July 31, 2017
124,484
 
$
15.01

 
85,000

 
$
1,275,510

 
$
27,967,308

 
 
 
 
 
 
 
 
 
 
August 1 - August 31, 2017
1,253,242
 
$
15.13

 
1,251,034

 
$
18,925,316

 
$
9,041,992

 
 
 
 
 
 
 
 
 
 
September 1 - September 30, 2017
625,906
 
$
14.51

 
622,300

 
$
9,029,252

 
$
12,740

 
 
 
 
 
 
 
 
 
 
    Total for the quarter
2,003,632
 
 
 
1,958,334

 
$
29,230,078

 
 

(a) Shares repurchased during the quarter include 45,298 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.

(b) On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. Our Board subsequently extended the program until December 31, 2017, and most recently in October 2017 announced that it had increased the total authorization to $120 million. The timing and amount of repurchases will depend upon our stock price, economic and market conditions, regulatory requirements, and other corporate considerations. We may initiate, suspend or discontinue purchases under the stock repurchase program at any time. The above table sets forth information regarding the purchases of our equity securities made under the repurchase program during the quarter prior to brokerage commissions of approximately $59,000.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information

None.


33


Item 6. Exhibits
Exhibit
Number
Description
2.1*
Membership Interest Purchase Agreement dated August 18, 2017 by and among MiMedx Group, Inc., a Florida corporation, Stability Biologics, LLC, a Georgia limited liability company (successor-in-interest to Stability Inc., a Florida corporation), each person that, as of January 13, 2016, was a stockholder of Stability Inc., a Florida corporation and a predecessor-in-interest to Stability LLC, and Brian Martin, as stockholder representative, incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K filed August 18, 2017.

 
 
3.1
Articles of Incorporation of MiMedx Group, Inc., as amended by Articles of Amendment to Articles of Incorporation filed on May 14, 2010, Articles of Amendment to Articles of Incorporation filed on August 8, 2012, Articles of Amendment to Articles of Incorporation filed on November 8, 2012, and Articles of Amendment to Articles of Incorporation filed on May 15, 2015, incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K filed March 1, 2017.
 
 
3.2
Bylaws of MiMedx Group, Inc., as amended as of December 14, 2016, incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed March 1, 2017.
 
 
10.1
Second Amendment to Credit Agreement dated October 12, 2015, by and among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A., and the other Lenders party thereto, incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K/A filed October 2, 2017.

 
 
31.1 #
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
31.2 #
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
32.1 #
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
32.2 #
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
101.INS #
XBRL Instance Document
 
 
101.SCH #
XBRL Taxonomy Extension Schema Document
 
 
101.CAL #
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.DEF #
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB #
XBRL Taxonomy Extension Label Linkbase Document
 
 
101.PRE #
XBRL Taxonomy Extension Presentation Linkbase Document
 
*
Schedules and exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. MiMedx agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request.

 
 
#
Filed herewith




34


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
MiMedix Group, Inc.
October 31, 2017
By:
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer
 
 
(principal financial and accounting officer)

35
 EX-31.1 2 exhibit311-certificationof.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Parker H. Petit, certify that:
 
1. I have reviewed this Form 10-Q for the quarter ended September 30, 2017, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 31, 2017
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-31.2 3 exhibit312-certificationof.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(A) AND 15d-14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
I, Michael J. Senken, certify that:

1. I have reviewed this Form 10-Q for the quarter ended September 30, 2017, of MiMedx Group, Inc.;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer  and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 31, 2017
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-32.1 4 exhibit321-certificationof.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Parker H. Petit, Chief Executive Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
October 31, 2017
/s/ Parker H. Petit
 
 
Parker H. Petit
 
 
Chief Executive Officer


 EX-32.2 5 exhibit322-certificationof.htm EXHIBIT 32.2 Exhibit


 Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of MiMedx Group, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Senken, Chief Financial Officer of the Company, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify, that to the best of my knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
October 31, 2017
/s/ Michael J. Senken
 
 
Michael J. Senken
 
 
Chief Financial Officer


 EX-101.INS 6 mdxg-20170930.xml XBRL INSTANCE DOCUMENT 0001376339 2017-01-01 2017-09-30 0001376339 2017-10-13 0001376339 2016-12-31 0001376339 2017-09-30 0001376339 2017-07-01 2017-09-30 0001376339 2016-01-01 2016-09-30 0001376339 2016-07-01 2016-09-30 0001376339 us-gaap:RetainedEarningsMember 2017-09-30 0001376339 us-gaap:TreasuryStockMember 2017-01-01 2017-09-30 0001376339 us-gaap:CommonStockMember 2016-12-31 0001376339 us-gaap:TreasuryStockMember 2017-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001376339 us-gaap:TreasuryStockMember 2016-12-31 0001376339 us-gaap:CommonStockMember 2017-09-30 0001376339 us-gaap:RetainedEarningsMember 2016-12-31 0001376339 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001376339 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001376339 2015-12-31 0001376339 2016-09-30 0001376339 us-gaap:PatentsMember 2017-01-01 2017-09-30 0001376339 us-gaap:PatentsMember 2016-01-01 2016-09-30 0001376339 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mdxg:StabilityBiologicsLLCMember 2017-09-30 2017-09-30 0001376339 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mdxg:StabilityBiologicsLLCMember 2017-09-30 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2017-09-30 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-09-30 0001376339 us-gaap:CapitalLeaseObligationsMember 2017-09-30 0001376339 us-gaap:LeaseholdImprovementsMember 2017-09-30 0001376339 us-gaap:FurnitureAndFixturesMember 2017-09-30 0001376339 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001376339 us-gaap:ConstructionInProgressMember 2017-09-30 0001376339 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001376339 us-gaap:ConstructionInProgressMember 2016-12-31 0001376339 us-gaap:EquipmentMember 2016-12-31 0001376339 us-gaap:EquipmentMember 2017-09-30 0001376339 us-gaap:LicensingAgreementsMember 2017-01-01 2017-09-30 0001376339 us-gaap:NoncompeteAgreementsMember 2017-01-01 2017-09-30 0001376339 us-gaap:PatentsMember 2017-09-30 0001376339 mdxg:TradeNamesAndTrademarksMember 2016-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2017-09-30 0001376339 us-gaap:PatentsMember 2016-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001376339 mdxg:TradeNamesAndTrademarksMember 2017-09-30 0001376339 us-gaap:NoncompeteAgreementsMember 2016-12-31 0001376339 mdxg:PatentsinProcessMember 2016-12-31 0001376339 mdxg:PatentsinProcessMember 2017-09-30 0001376339 us-gaap:LicensingAgreementsMember 2016-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-12-31 0001376339 us-gaap:LicensingAgreementsMember 2017-09-30 0001376339 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-09-30 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2017-09-30 0001376339 us-gaap:CustomerRelationshipsMember 2017-09-30 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2017-01-01 2017-09-30 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 0001376339 mdxg:SurgicalBiologicsMember mdxg:TradeNamesAndTrademarksMember 2011-01-05 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 us-gaap:DistributionRightsMember 2017-09-30 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-29 0001376339 mdxg:StabilityBiologicsLLCMember 2017-07-01 2017-09-30 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:TradeNamesAndTrademarksMember 2016-01-13 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:StabilityBiologicsLLCMember 2017-01-01 2017-09-30 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0001376339 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2016-07-01 2016-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001376339 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange4Member 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange4Member 2017-09-30 0001376339 mdxg:PriceRange6Member 2017-09-30 0001376339 mdxg:PriceRange2Member 2017-09-30 0001376339 mdxg:PriceRange1Member 2017-09-30 0001376339 mdxg:PriceRange6Member 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange3Member 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange5Member 2017-09-30 0001376339 mdxg:PriceRange3Member 2017-09-30 0001376339 mdxg:PriceRange2Member 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange1Member 2017-01-01 2017-09-30 0001376339 mdxg:PriceRange5Member 2017-01-01 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2017-09-30 0001376339 us-gaap:RestrictedStockMember 2016-12-31 0001376339 2014-05-12 0001376339 us-gaap:CommonStockMember mdxg:ConsultantMember 2017-01-01 2017-09-30 0001376339 us-gaap:SubsequentEventMember 2017-10-26 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2017-07-01 2017-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001376339 us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001376339 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-01 2016-09-30 0001376339 us-gaap:ScenarioForecastMember 2017-01-01 2017-12-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-07-01 2016-09-30 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 us-gaap:PendingLitigationMember 2017-06-30 0001376339 us-gaap:StandbyLettersOfCreditMember 2017-09-30 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2017-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2017-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-01-01 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2017-01-01 2017-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-07-01 2016-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2017-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2017-07-01 2017-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-07-01 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2017-01-01 2017-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2017-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-07-01 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2017-07-01 2017-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2017-07-01 2017-09-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2017-06-30 0001376339 mdxg:AllowanceforObsolescenceMember 2016-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2017-01-01 2017-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-09-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2017-06-30 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-09-30 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-06-30 iso4217:USD xbrli:shares mdxg:plan xbrli:pure mdxg:segment iso4217:USD mdxg:claim xbrli:shares false --12-31 Q3 2017 2017-09-30 10-Q 0001376339 111034873 Large Accelerated Filer MIMEDX GROUP, INC. 630000 150000 3190000 21614000 0.03 16940000 400000 1510000 4205000 1702000 5618000 10011000 6992000 6510000 35000000 1 2 4 515000 144000 P30D 109000 11436000 8767000 67151000 59581000 5768000 2329000 10941000 8613000 8505000 10954000 626000 1932000 626000 1932000 P13Y P7Y P4Y P19Y 161261000 163446000 3337000 3337000 4701000 109000 159000 4433000 13826000 300000 520000 13006000 5306000 119000 148000 5039000 15232000 393000 425000 14414000 136000 135000 631000 1889000 418000 1451000 6369189 5704112 665077 6265811 5767469 498342 10630489 7916564 2713925 10077728 7985521 2092207 193263000 178707000 126538000 114110000 20427000 17644000 200000 8740000 0 8710000 0 28486000 18338000 34391000 36522000 -10148000 2131000 0.001 0.001 150000000 150000000 110212547 112703926 109862787 111035248 110000 112000 10560000 495000 1470000 1428000 2634000 2826000 1707000 7997000 23338000 9599000 26972000 0.0225 0.015 0.12 500000 9114000 17671000 -449000 -8557000 838000 2394000 1013000 3074000 2405000 3487000 309000 300000 11857000 2800000 1610000 1446000 2000000 0.03 0.06 0.16 0.28 0.03 0.06 0.15 0.26 -0.335 -0.140 0.351 0.281 0.315 0.154 0.094 12365000 15092000 P2Y15D 32910620 98900 5340000 237000 942000 950000 950000 950000 9091000 1399000 830000 14839000 4271000 510000 1009000 120000 8712000 3761000 13000 7690000 5330000 390000 830000 6790000 9369000 515000 144000 663000 4274000 0 0 4274000 4274000 20203000 20200000 19894000 56432000 151801000 74974000 206620000 0 357000 4616000 9477000 13073000 26178000 -5737000 1295000 2984000 -4384000 -3675000 5737000 5737000 637000 8289000 -3941000 478000 7671000 -5165000 2020000 -2228000 2621000 -3438000 -4223000 2873000 3599000 -3738000 -286000 402000 -82000 -794000 2023000 792000 2618000 1458000 25000 1742000 1008000 25000 1008000 25000 450000 30260000 16887000 23268000 10377000 118000 119000 10817000 5554000 18642000 11408000 17814000 10419000 1148000 690000 828000 989000 6677000 5164000 1471000 203000 453000 1311000 403000 1244000 P6Y 52000 60263000 36235000 193263000 178707000 50732000 35159000 3487000 0 50000000 4 7 7 6 5 -8849000 -35801000 -10447000 -4142000 9148000 42074000 3321000 6493000 17457000 29853000 29853000 1 4703000 9731000 8842000 22241000 1288000 926000 354000 3391000 1482000 358000 821000 1076000 8600 -87000 -254000 -43000 -337000 43923000 106000 0 892000 3337000 7631000 0 21000 22000 996000 5301000 3998000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 5894000 6662000 -10378000 -44032000 3000000 0 2548000 11590000 22291000 3300000 8666000 7051000 3274000 24218000 2583000 9316000 9203000 3116000 13786000 13264000 1000000 427000 2919000 8582000 5481000 14430000 -26155000 3698000 50000 64429000 175139000 84573000 233592000 48179000 131599000 60233000 168498000 13826000 15232000 283198 8.67 3041078 9.23 3828445 5128876 8.53 8.97 1457449 8.42 10043166 3.26 17994945 68991 25839 0 0 86178050 12552608 10040009 3.61 3.30 86176954 9976636 3.30 4.80 5.79 6.54 0.00 0.70 1.10 2.45 4.19 6.49 9.90 9976636 1094429 4290379 854001 1989205 1683625 64997 10040009 1094429 4290379 854001 1989205 1713328 98667 1.09 1.65 3.75 6.38 9.78 10.99 86042771 P4Y7M2D P4Y7M6D 3.26 0.91 1.30 2.77 5.36 7.26 10.38 3.30 0.91 1.30 2.77 5.36 7.30 10.38 P4Y7M6D P2Y9M18D P3Y8M12D P5Y0M0D P5Y8M12D P6Y4M24D P7Y2M12D 110212547 349760 112703926 1668678 358861 441009 43344 17539 17539 17539 283198 1393446 -1630093 2417769 1097933 -1319836 2684270 3346000 0 346000 166000 41000 166000 125000 0 -2717000 2717000 0 -13108000 1000 13107000 15232000 15232000 11590000 -2697000 1000 14286000 24801000 10000000 120000000 13000 133000000 161261000 110000 -26155000 -2216000 142472000 163446000 112000 3698000 -24784000 349760 1668678 3644327 2216000 24784000 44032000 44032000 397000 3270000 1262000 1780000 4086000 2191000 708000 4350000 2262000 828000 4842000 4894000 1113000 7219000 3461000 989000 6960000 3479000 339000 800000 2591000 1910000 1635000 5917000 212000 150000 1288000 953000 2600000 5794000 1411000 536000 2520000 1599000 555000 4917000 336000 409000 1270000 792000 482000 7209000 6369189 6265811 10630489 10077728 112361179 112193701 117501925 116547006 105991990 105927890 106871436 106469278 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know-How (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the license was fully amortized. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$663,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization over the life of the patents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability, Inc. As a result, the Company recorded intangible assets for Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$6,790,000</font><font style="font-family:inherit;font-size:10pt;">, Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$5,330,000</font><font style="font-family:inherit;font-size:10pt;">, Non-compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$390,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on March 1, 2017.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes, after the measurement period has expired, to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities:</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Commitments</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the capital leases noted above in Note 5, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next </font><font style="font-family:inherit;font-size:10pt;">six years</font><font style="font-family:inherit;font-size:10pt;"> and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual lease payments, meeting space commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Twelve months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,244,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,311,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was approximately </font><font style="font-family:inherit;font-size:10pt;">$403,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$453,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is allocated among cost of sales, research and development and selling, general and administrative expenses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Letters of Credit</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$52,000</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Untitled Letter and Draft Guidance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, the Company would need a biologics license to lawfully market those micronized products (the "Untitled Letter"). Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's micronized allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company continues to market its micronized products but is also pursuing the Biologics License Application (&#8220;BLA&#8221;) process for certain of its micronized products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the FDA issued for comment &#8220;Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.&#8221; Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA&#8217;s statutory authority, is inconsistent with existing human cells, tissues, and cellular and tissue-based products ("HCT/P") regulations and the FDA&#8217;s prior positions, and is internally inconsistent and scientifically unsound.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from the FDA on the draft guidances, but anticipates this will be a lengthy process.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with current good manufacturing processes ("cGMP"). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Former Employee Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 13, 2016, the Company filed lawsuits against former employees Jess Kruchoski (in the lawsuit styled&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">MiMedx Group, Inc. v. Academy Medical, LLC, et. al.</font><font style="font-family:inherit;font-size:10pt;">&#160;in the County Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the &#8220;Florida Action&#8221;)) and Luke Tornquist (in the lawsuit styled&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">MiMedx Group, Inc., v. Luke Tornquist</font><font style="font-family:inherit;font-size:10pt;">&#160;in the Superior Court for Cobb County, Georgia, which was removed to the United States District Court for the Northern District of Georgia (the &#8220;Georgia Action&#8221;)).&#160; Both the Florida and Georgia Actions assert claims against Messrs. Kruchoski and Tornquist that each of them violated their restrictive covenants entered into with the Company, that each of them misappropriated trade secrets of the Company, that each of them tortiously interfered with contracts between the Company and its customers and employees and that each of them breached his duty of loyalty owed to the Company, among other claims. The Company sought injunctive relief against each of Mr. Kruchoski and Tornquist to enforce its restrictive covenants in place with each of them. The Company obtained consent injunctions from each party enforcing those covenants. The Company is also seeking monetary damages in an amount to be determined at trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to vigorously pursue its claims asserted in all of these actions and also to vigorously defend against the lawsuits and counterclaims asserted against it.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to diligently enforce its intellectual property against several entities. Currently, there are&#160;</font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#160;actions pending, as described below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Liventa Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. (formerly known as AFCell Medical, Inc.) ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of the Company's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached a settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company asserts that Liventa, Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. Trial has been set for the week of January 22, 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Bone Bank Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. On September 7, 2017, the Court granted partial summary judgment in defendants&#8217; favor on a portion of the claim. The Company filed a motion for reconsideration on October 4, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The NuTech Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Vivex Action</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (&#8220;Vivex&#8221;) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "'494" patent). Vivex answered the Company&#8217;s complaint and filed counterclaims of non-infringement and invalidity. On January 4, 2017, the Court granted a joint motion to stay the proceedings pending the outcome of the Bone Bank Action.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">IPRs</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review ("IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "'687" patent) and the '494 patent, while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all&#160;</font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all&#160;</font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only&#160;</font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. The Company decided not to appeal the decision, as it impacted a non-core patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">&#160;challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.&#160; The Company filed an appeal of the PTAB&#8217;s decision regarding the '437 patent. On September 14, 2017, the Federal Circuit affirmed the PTAB&#8217;s decision regarding the &#8216;437 patent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Capitol Forum Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 21, 2017, MiMedx filed a lawsuit against DBW Partners LLC d/b/a The Capitol Forum (the &#8220;Capitol Forum&#8221;), Trevor Baine, Teddy Downey, Jake Williams, Miles Pulsford, Matt Treacy and John Does 1-100 (collectively, the &#8220;Capitol Defendants&#8221;) in the United States District Court for the District of Columbia. The Company has brought claims for defamation, libel, slander, tortious interference, false light, and violations of the Lanham Act in relation to the Capitol Defendants publishing articles and sending emails to shareholders that are false and misleading for the purpose of negatively impacting the price of MiMedx stock. The Capitol Defendants have not yet responded to the Company&#8217;s complaint.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">The Aurelius Value and Viceroy Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 4, 2017, the Company and Sean McCormack (a Company employee) filed a lawsuit against Sparrow Fund Management LP a/k/a Aurelius Value, Viceroy Research, John Fichthorn, BR Dialectic Capital Management LLC and John Does 1-10 in the United States District Court for the Southern District of New York asserting claims for libel, slander, defamation, false light and tortious interference based on false and misleading &#8220;research&#8221; reports and other false and misleading statements allegedly published in order to manipulate the Company's stock. Defendants Sparrow, Fichthorn, and BR Dialectic have filed motions to dismiss MiMedx&#8217;s complaint which are pending before the court.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual lease payments, meeting space commitments are as follows (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Twelve months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,826</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">. In September 2017, the expiration date of the credit agreement was extended to October 12, 2019. The Credit Agreement also provides for an uncommitted incremental facility of up to </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;">, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. The obligations of the loan parties under the Credit Agreement and the other credit documents are secured by liens on and security interests in substantially all of the assets of each of the loan parties and a pledge of the equity interests of each subsidiary owned by a loan party, subject to certain customary exclusions. Borrowings under the facility will bear interest at LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">1.5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">. Fees paid in connection with the initiation of the credit facility totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">. These deferred financing costs are being amortized to interest expense over the initial life of the facility. The Credit Agreement contains customary representations, warranties, covenants and events of default, including restrictions on certain payments of dividends by the Company. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> outstanding revolving loans under the credit facility, and the Company was in compliance with all covenants under the Credit Agreement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;">&#160; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the &#8220;Assumed 2006 Plan&#8221;); the MiMedx Inc. 2007 Assumed Stock Plan (the &#8220;Assumed 2007 Plan&#8221;); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the &#8220;Assumed 2005 Plan&#8221;). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,417,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,839</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,040,009</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,178,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,042,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at September 30, 2017 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,043,166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,176,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture-adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$17,994,945</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.70 - $1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.10 - $1.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,290,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,290,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.45 - $3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,989,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,989,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.49 - $9.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,713,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,667</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,997</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,040,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense related to granted stock options at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$98,900</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense ratably through January 2018.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#160;&#160;Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.&#160;&#160;The term of employee options granted is derived using the &#8220;simplified method,&#8221; which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.&#160;&#160;The term for non-employee options is generally based upon the contractual term of the option.&#160;&#160;The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> options granted during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows and includes </font><font style="font-family:inherit;font-size:10pt;">17,539</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$166,000</font><font style="font-family:inherit;font-size:10pt;"> which were issued under the 2016 Plan to a consultant in return for services performed:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,828,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,041,078</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,457,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,128,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.97</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$32,910,620</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized share-based compensation expense related to time-based, nonvested restricted stock.&#160;&#160;That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.04</font><font style="font-family:inherit;font-size:10pt;"> years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized share-based compensation expense as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,414</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,232</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:6px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. Our Board subsequently extended the program until December 31, 2017, and increased the total authorization to </font><font style="font-family:inherit;font-size:10pt;">$120 million</font><font style="font-family:inherit;font-size:10pt;"> as of October 26, 2017. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">3,644,327</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$43,923,000</font><font style="font-family:inherit;font-size:10pt;"> before brokerage commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$109,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;"> of availability remaining under the repurchase program. In addition, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">358,861</font><font style="font-family:inherit;font-size:10pt;"> shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company reissued </font><font style="font-family:inherit;font-size:10pt;">2,684,270</font><font style="font-family:inherit;font-size:10pt;"> shares from the treasury for restricted stock grants and stock option exercises, net of forfeitures, with an aggregate carrying value of approximately </font><font style="font-family:inherit;font-size:10pt;">$24,801,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> of Stability Biologics, LLC</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2017, we completed the previously announced divestiture (the &#8220;Stability Divestiture&#8221;) of our wholly-owned subsidiary, Stability Biologics, LLC, a Georgia limited liability company (successor-in-interest to Stability Inc., a Florida corporation) (&#8220;Stability LLC&#8221;), pursuant to the Membership Interest Purchase Agreement (&#8220;Agreement&#8221;) by and among the Company, Stability LLC, each person that, as of January 13, 2016, was a stockholder (the &#8220;Stockholders&#8221;) of Stability Inc., a Florida corporation and a predecessor-in-interest to Stability LLC ("Stability, Inc."), and Brian Martin, as stockholder representative, the terms of which were previously disclosed in the Current Report on Form 8-K dated August 18, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the assets divested and consideration received follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:508px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:365px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets divested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,487</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total net assets divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,940</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transaction costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consideration received</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-trade receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Extinguishment of earn out liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total consideration received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,614</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain on sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In accordance with ASC 350-20-35-52 when a portion of a reporting unit is disposed of, goodwill associated with that business shall be included in the carrying amount of the business in determining the gain on disposal. In accordance with ASC 350-20-35-53, the amount of goodwill to be included in that carrying amount shall be based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. Based on an estimated approximate fair value of Stability LLC compared to the business retained, approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> out of the total goodwill of </font><font style="font-family:inherit;font-size:10pt;">$20.2 million</font><font style="font-family:inherit;font-size:10pt;"> residing in the reporting unit was included in the carrying amount of the business sold. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total gain on the Stability Divestiture of </font><font style="font-family:inherit;font-size:10pt;">$10,011,000</font><font style="font-family:inherit;font-size:10pt;"> is comprised of a pretax book gain of </font><font style="font-family:inherit;font-size:10pt;">$4,274,000</font><font style="font-family:inherit;font-size:10pt;"> and an associated tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$5,737,000</font><font style="font-family:inherit;font-size:10pt;">, which consists principally of the write off of deferred tax liabilities related to Stability LLC.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method.&#160;</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.&#160;&#160;Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,871,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,991,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,469,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,927,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options and restricted stock outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,630,489</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,077,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,501,925</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,361,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,547,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,193,701</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,916,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,704,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,985,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,713,925</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">665,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,092,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,630,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,077,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rate for the three months ended September 30, 2017 was </font><font style="font-family:inherit;font-size:10pt;">(33.5)%</font><font style="font-family:inherit;font-size:10pt;"> and reflects discrete tax benefits related to the Stability Divestiture of </font><font style="font-family:inherit;font-size:10pt;">$5,737,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1,702,000</font><font style="font-family:inherit;font-size:10pt;"> primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was </font><font style="font-family:inherit;font-size:10pt;">15.4%</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended September 30, 2017 and </font><font style="font-family:inherit;font-size:10pt;">28.1%</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended September 30, 2016, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effective tax rate for the nine months ended September 30, 2017 was </font><font style="font-family:inherit;font-size:10pt;">(14.0)%</font><font style="font-family:inherit;font-size:10pt;"> and reflects discrete tax benefits related to the Stability Divestiture of </font><font style="font-family:inherit;font-size:10pt;">$5,737,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$5,618,000</font><font style="font-family:inherit;font-size:10pt;"> primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was </font><font style="font-family:inherit;font-size:10pt;">9.4%</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended September 30, 2017 and </font><font style="font-family:inherit;font-size:10pt;">31.5%</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended September 30, 2016, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the end of September 2017, the projected annual effective tax rate for 2017 is </font><font style="font-family:inherit;font-size:10pt;">35.1%</font><font style="font-family:inherit;font-size:10pt;"> (excluding discrete items).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents &amp; Know-How (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer &amp; Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames &amp; Trademarks (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Process Research &amp; Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.&#160;&#160;Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the license was fully amortized. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.&#160;&#160;As a result, the Company recorded intangible assets for Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research &amp; Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents &amp; Know-How under intangible assets subject to amortization. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$663,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents &amp; Know-How subject to amortization over the life of the patents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability, Inc. As a result, the Company recorded intangible assets for Patents &amp; Know-How of </font><font style="font-family:inherit;font-size:10pt;">$6,790,000</font><font style="font-family:inherit;font-size:10pt;">, Customer &amp; Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$5,330,000</font><font style="font-family:inherit;font-size:10pt;">, Non-compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames &amp; Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$390,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2017, the Company completed the Stability Divestiture which resulted in the transfer of intangible assets acquired in 2016 and the acquisition of a Distribution Agreement valued at </font><font style="font-family:inherit;font-size:10pt;">$510,000</font><font style="font-family:inherit;font-size:10pt;"> and a Non-compete Agreement valued at </font><font style="font-family:inherit;font-size:10pt;">$120,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,451,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,889,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$418,000</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;">$631,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">for the</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2016</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, respectively.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended September 30, 2017, approximately </font><font style="font-family:inherit;font-size:10pt;">$1,932,000</font><font style="font-family:inherit;font-size:10pt;"> of accumulated amortization expense was eliminated in connection with the Stability Divestiture. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,554</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,817</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(989</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(828</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or market, using the first-in, first-out ("FIFO") method.&#160;&#160;Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations.&#160;Labor and overhead costs are absorbed through the various production processes until the work order closes.&#160;Historical yields and normal capacities are utilized in the calculation of production overhead rates.&#160;&#160;Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible Assets in the Condensed Consolidated Balance Sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued and Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. We are in the process of completing our procedures for adoption of the standard. We have identified one revenue stream from our contracts with customers: product sales. Based upon the results of our work to date we have elected the modified retrospective method as we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)." The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," which simplifies several aspects of the accounting for share-based payment award transactions including (a) income tax consequences; (b) classification of awards as either debt or equity liabilities; and (c) classification on the statement of cash flows.&#160; The amendments are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&#160; The Company has adopted this ASU as of January 1, 2017. The primary amendment impacting the Company's financial statements is the requirement for excess tax benefits or shortfalls on the exercise of share-based compensation awards to be presented in income tax expense in the Consolidated Statements of Income during the period the award is exercised as opposed to being recorded in additional paid-in capital on the Consolidated Balance Sheets.&#160; The excess tax benefit or shortfall is calculated as the difference between the fair value of the award on the date of exercise and the fair value of the award used to measure the expense to be recognized over the service period.&#160; Changes are required to be applied prospectively to all excess tax benefits and deficiencies resulting from the exercise of awards after the date of adoption. The ASU requires a "modified retrospective" approach application for excess tax benefits that were not previously recognized in situations where the tax deduction did not reduce current taxes payable. For the three-month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$1,510,000</font><font style="font-family:inherit;font-size:10pt;"> related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$4,205,000</font><font style="font-family:inherit;font-size:10pt;"> related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. As the end result is dependent on the future value of the Company's stock as well as the timing of employee exercises, the amount of future impact cannot be quantified at this time. The Company has elected to continue to estimate forfeitures expected to occur to determine the share-based compensation expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments.&#8221; The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04,"Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment." The update eliminates Step 2 from the goodwill impairment test. This ASU is effective for fiscal years beginning after December 15, 2019. The amendments in this update should be applied on a prospective basis. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&#160;&#160;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.&#160;&#160;Changes to GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of Accounting Standards Updates (&#8220;ASU&#8217;&#8217;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;).&#160;&#160;In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.&#160;&#160;Operating results for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results that may be expected for the fiscal year.&#160;&#160;The balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, included in the Company's Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on March 1, 2017.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The&#160;MiMedx&#160;allograft product families include our: dHACM family with AmnioFix&#174; and EpiFix&#174; brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord&#174; and AmnioCord&#174; brands; and Placental Collagen family with CollaFix&#174; and AmnioFill&#174; brands. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;&#160; EpiCord and AmnioCord are derived from the umbilical cord; and&#160;CollaFix&#174; is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair and is in development.&#160;(Our former Physio product is owned by our former subsidiary, Stability Biologics, LLC which we divested effective September 30, 2017). See Note 3, Divestiture of Stability Biologics, LLC, below.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,583</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,505</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,786</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$427,000</font><font style="font-family:inherit;font-size:10pt;"> of equipment covered under capital leases. The corresponding liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$8,600</font><font style="font-family:inherit;font-size:10pt;"> is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. The interest rate for the lease is approximately </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> with a maturity date of January 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also included in net property and equipment is approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross depreciation expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$3,074,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,394,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately </font><font style="font-family:inherit;font-size:10pt;">$1,013,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$838,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the three and nine months ended September 30, 2017 approximately </font><font style="font-family:inherit;font-size:10pt;">$626,000</font><font style="font-family:inherit;font-size:10pt;"> of accumulated depreciation expense and </font><font style="font-family:inherit;font-size:10pt;">$2,000,000</font><font style="font-family:inherit;font-size:10pt;"> in gross book value of property and equipment was eliminated in connection with the Stability Divestiture.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,583</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,954</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,505</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,786</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Notes Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's notes receivable as of September 30, 2017 are included in Other Assets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S., and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our customers and stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the Company&#8217;s sales to Government accounts, including the Department of Veterans Affairs, were historically made through a distributor relationship with AvKARE Inc., which is a veteran-owned General Services Administration Federal Supply Schedule contractor. The Company's agreement with AvKARE expired on June 30, 2017. Upon expiration of the agreement, the Company had an obligation to repurchase AvKARE&#8217;s remaining inventory within 90 days in accordance with the terms of the agreement. As of September 30, 2017, the Company has satisfied the repurchase obligation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the Company&#8217;s revenue is generated from consignment inventory maintained at hospitals or physicians' offices. Significant terms of our consignment agreements state that title to the inventory remains with the Company until the product, which has been segregated by the consignee, is withdrawn and therefore purchased by the consignee. The consignee accepts all risk of loss and full responsibility for any product in the consignment inventory that may be opened, lost, stolen or damaged. The Company recognizes revenue when we are notified that product has been used or implanted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements. These estimates have historically been materially consistent with actual results.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their creditworthiness, and current economic conditions. We only record revenue when collectability is reasonably assured.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issuance of 441,009 shares in connection with acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the assets divested and consideration received follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:508px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:365px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets divested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,487</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total net assets divested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,940</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transaction costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consideration received</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-trade receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Extinguishment of earn out liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total consideration received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,614</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain on sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In accordance with ASC 350-20-35-52 when a portion of a reporting unit is disposed of, goodwill associated with that business shall be included in the carrying amount of the business in determining the gain on disposal. In accordance with ASC 350-20-35-53, the amount of goodwill to be included in that carrying amount shall be based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. Based on an estimated approximate fair value of Stability LLC compared to the business retained, approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> out of the total goodwill of </font><font style="font-family:inherit;font-size:10pt;">$20.2 million</font><font style="font-family:inherit;font-size:10pt;"> residing in the reporting unit was included in the carrying amount of the business sold. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,871,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,991,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,469,278</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,927,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options and restricted stock outstanding(a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,630,489</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,077,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117,501,925</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,361,179</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,547,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,193,701</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,916,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,704,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,985,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,713,925</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">665,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,092,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">498,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,630,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,369,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,077,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,265,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized share-based compensation expense as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,039</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,433</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,414</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,006</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,232</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,164</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,554</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,817</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,408</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(989</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(828</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.70 - $1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.10 - $1.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,290,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,290,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.45 - $3.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">854,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,989,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,989,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.49 - $9.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,713,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,667</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,997</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,040,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Price</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in years)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,417,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,839</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,040,009</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,178,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at September 30, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,976,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,042,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at September 30, 2017 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,043,166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,176,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture-adjusted unvested shares.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to restricted stock awards for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows and includes </font><font style="font-family:inherit;font-size:10pt;">17,539</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$166,000</font><font style="font-family:inherit;font-size:10pt;"> which were issued under the 2016 Plan to a consultant in return for services performed:&#160; </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,828,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,041,078</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,457,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.67</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,128,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.97</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Three and Nine Months Ended September 30, 2017 and 2016 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Period</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns, discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,288</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,270</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(536</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns, discounts and allowances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,411</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns, discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,794</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,209</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended September 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for sales returns, discounts and allowances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,910</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,599</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">708</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending&#160;December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Estimated amortization expense for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, includes only amortization to be recorded after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please see Note 2 to the Company's Consolidated Financial Statements included in the Company&#8217;s Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, for a description of all significant accounting policies.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowance for doubtful accounts is the Company&#8217;s best estimate of the amount of probable credit losses in the Company&#8217;s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Notes Receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's notes receivable as of September 30, 2017 are included in Other Assets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are valued at the lower of cost or market, using the first-in, first-out ("FIFO") method.&#160;&#160;Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations.&#160;Labor and overhead costs are absorbed through the various production processes until the work order closes.&#160;Historical yields and normal capacities are utilized in the calculation of production overhead rates.&#160;&#160;Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S., and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our customers and stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the Company&#8217;s sales to Government accounts, including the Department of Veterans Affairs, were historically made through a distributor relationship with AvKARE Inc., which is a veteran-owned General Services Administration Federal Supply Schedule contractor. The Company's agreement with AvKARE expired on June 30, 2017. Upon expiration of the agreement, the Company had an obligation to repurchase AvKARE&#8217;s remaining inventory within 90 days in accordance with the terms of the agreement. As of September 30, 2017, the Company has satisfied the repurchase obligation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the Company&#8217;s revenue is generated from consignment inventory maintained at hospitals or physicians' offices. Significant terms of our consignment agreements state that title to the inventory remains with the Company until the product, which has been segregated by the consignee, is withdrawn and therefore purchased by the consignee. The consignee accepts all risk of loss and full responsibility for any product in the consignment inventory that may be opened, lost, stolen or damaged. The Company recognizes revenue when we are notified that product has been used or implanted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements. These estimates have historically been materially consistent with actual results.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their creditworthiness, and current economic conditions. We only record revenue when collectability is reasonably assured.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of operations of acquired companies are included in the Company&#8217;s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes, after the measurement period has expired, to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$144,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first nine months of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company capitalized approximately </font><font style="font-family:inherit;font-size:10pt;">$515,000</font><font style="font-family:inherit;font-size:10pt;"> of patent costs during the first nine months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued and Adopted Accounting Standards</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, &#8220;Revenue Recognition - Revenue from Contracts with Customers&#8221; (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. We are in the process of completing our procedures for adoption of the standard. We have identified one revenue stream from our contracts with customers: product sales. Based upon the results of our work to date we have elected the modified retrospective method as we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)." The core principle of Topic 842 is that a lessee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," which simplifies several aspects of the accounting for share-based payment award transactions including (a) income tax consequences; (b) classification of awards as either debt or equity liabilities; and (c) classification on the statement of cash flows.&#160; The amendments are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&#160; The Company has adopted this ASU as of January 1, 2017. The primary amendment impacting the Company's financial statements is the requirement for excess tax benefits or shortfalls on the exercise of share-based compensation awards to be presented in income tax expense in the Consolidated Statements of Income during the period the award is exercised as opposed to being recorded in additional paid-in capital on the Consolidated Balance Sheets.&#160; The excess tax benefit or shortfall is calculated as the difference between the fair value of the award on the date of exercise and the fair value of the award used to measure the expense to be recognized over the service period.&#160; Changes are required to be applied prospectively to all excess tax benefits and deficiencies resulting from the exercise of awards after the date of adoption. The ASU requires a "modified retrospective" approach application for excess tax benefits that were not previously recognized in situations where the tax deduction did not reduce current taxes payable. For the three-month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$1,510,000</font><font style="font-family:inherit;font-size:10pt;"> related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$4,205,000</font><font style="font-family:inherit;font-size:10pt;"> related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. As the end result is dependent on the future value of the Company's stock as well as the timing of employee exercises, the amount of future impact cannot be quantified at this time. The Company has elected to continue to estimate forfeitures expected to occur to determine the share-based compensation expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments.&#8221; The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04,"Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment." The update eliminates Step 2 from the goodwill impairment test. This ASU is effective for fiscal years beginning after December 15, 2019. The amendments in this update should be applied on a prospective basis. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</font></div></div> EX-101.SCH 7 mdxg-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Contractual Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Divestiture of Stability Biologics, LLC link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Divestiture of Stability Biologics, LLC - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Divestiture of Stability Biologics, LLC - Summary of Assets Transferred and Consideration Received (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Divestiture of Stability Biologics, LLC (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Equity - Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mdxg-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mdxg-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mdxg-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Amendment Flag Document Period End Date Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Treasury Stock Treasury Stock [Member] Earnings (Deficit) Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (in shares) Shares, Outstanding Balance, beginning of period Stockholders' Equity Attributable to Parent Share-based compensation expense Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Restricted stock shares canceled/forfeited Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Restricted stock shares cancelled/forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Shares issued for services performed Stock Issued During Period, Value, Issued for Services Shares issued for services performed (in shares) Stock Issued During Period, Shares, Issued for Services Share repurchase (in shares) Treasury Stock, Shares, Acquired Share repurchase Treasury Stock, Value, Acquired, Cost Method Shares repurchased for tax withholding (in shares) Shares Paid for Tax Withholding for Share Based Compensation Shares repurchased for tax withholding Adjustments Related to Tax Withholding for Share-based Compensation Net income Net Income (Loss) Attributable to Parent Balance (in shares) Balance, end of period Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses Licensing Agreements [Member] Patents and know-how Patents [Member] Customer & supplier relationships Customer Relationships [Member] Non compete agreements Noncompete Agreements [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Tradenames & trademarks Trade names and trademarks [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style. In process research & development In Process Research and Development [Member] Patents in process Patents in Process [Member] Patents in Process Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Surgical Biologics, LLC Surgical Biologics [Member] Represents Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia. which the Company acquired through an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and Ramp Capital Investments, LLC on December 21, 2010. Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stability Biologics, LLC Stability Biologics, LLC [Member] Stability Biologics, LLC Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Weighted average amortization lives Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Gross carrying value Finite-Lived Intangible Assets, Gross Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Total Intangible Assets, Gross (Excluding Goodwill) Less Accumulated amortization and impairment charges Intangible Assets, Accumulated Amortization And Impairment Charges Intangible Assets, Accumulated Amortization And Impairment Charges Net Intangible Assets, Net (Excluding Goodwill) Acquisition price Payments to Acquire Intangible Assets Maximum time of approval Period of approval, maximum The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. Fair value of earn-out Business Combination, Contingent Consideration, Liability Contingent royalty to be paid to licensor Contingent royalty to be paid to licensor Royalty payment percentage on all commercial sales revenue from the licensed products. Annual royalty payment, minimum Royalty Expense Finite lived intangible assets Finite-lived Intangible Assets Acquired Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract] Supplemental disclosure of cash flow and non cash investing and financing activities [Abstract] -- None. No documentation exists for this element. -- Cash paid for interest Interest Paid Income taxes paid Income Taxes Paid Share issuance of 441,009 shares in connection with acquisition Stock Issued During Period, Value, Acquisitions Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively Shares issued in connection with business combination (in shares) Stock Issued During Period, Shares, Acquisitions Shares issued for services performed (in shares) Valuation and Qualifying Accounts [Abstract] Schedule II - Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Discontinued Operations and Disposal Groups [Abstract] Divestiture of Stability Biologics, LLC Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Debt Disclosure [Abstract] Credit Facility Debt Disclosure [Text Block] Equity [Abstract] Stock Options Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Stock Options Outstanding and Exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Restricted Stock Awards Roll Forward Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Allocation of Share-based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Assets divested Disposal Group, Including Discontinued Operation, Assets [Abstract] Trade receivables Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Inventories Disposal Group, Including Discontinued Operation, Inventory Prepaid expenses and other assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets Goodwill Disposal Group, Including Discontinued Operation, Goodwill Intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets Property and equipment, net of accumulated depreciation Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Total assets divested Disposal Group, Including Discontinued Operation, Assets Liabilities divested Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Accounts payable and accrued liabilities Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities Total liabilities divested Disposal Group, Including Discontinued Operation, Liabilities Total net assets divested Disposal Group, Including Discontinued Operation, Assets (Liabilities) Disposal Group, Including Discontinued Operation, Assets (Liabilities) Transaction costs Disposal Group, Including Discontinued Operation, Transaction Costs Disposal Group, Including Discontinued Operation, Transaction Costs Consideration received Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Non-trade receivable Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Non-trade Receivables Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Non-trade Receivables Note receivable Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Note Receivable Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Note Receivable Intangible assets Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Intangible Assets Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Intangible Assets Extinguishment of earn out liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Total consideration received Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Total Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Total Gain on sale Gain (Loss) on Disposition of Business Goodwill Goodwill Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of intangible assets Amortization of Intangible Assets Amortization of inventory fair value step-up Inventory Write-down Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Impairment of intangible assets Impairment of Intangible Assets, Finite-lived Share-based compensation Share-based Compensation Change in deferred income taxes Deferred Income Taxes and Tax Credits Gain on divestiture Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Deferred Compensation Accrued expenses Increase (Decrease) in Accrued Liabilities Income taxes Increase (Decrease) in Accrued Taxes Payable Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of equipment Payments to Acquire Machinery and Equipment Stability acquisition Payments to Acquire Businesses, Net of Cash Acquired Fixed maturity securities redemption Proceeds from Sale and Maturity of Held-to-maturity Securities Patent application costs Payments for Application Costs, Patent Payments for Application Costs, Patent Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Share repurchase under repurchase plan Proceeds from (Repurchase of) Equity Share repurchase for tax withholdings on vesting of restricted stock Payments Related to Tax Withholding for Share-based Compensation Deferred financing costs Payments of Debt Issuance Costs Payments under capital lease obligations Payments to Acquire Equipment on Lease Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Commitments and Contingencies Disclosure [Abstract] Estimated Annual Lease, Royalty and Employment Agreement Expenses Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $0.70 - $1.09 Price Range 1 [Member] Price Range 1 [Member] $1.10 - $1.65 Price Range 2 [Member] Price Range 2 [Member] $2.45 - $3.75 Price Range 3 [Member] Price Range 3 [Member] $4.19 - $6.38 Price Range 4 [Member] Price Range 4 [Member] $6.49 - $9.78 Price Range 5 [Member] Price Range 5 [Member] $9.90 - $10.99 Price Range 6 [Member] Price Range 6 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of share-based compensation plans (plan) Number of share based compensation plans The number of share-based compensation the company maintains. Number of shares [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Unvested options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (in shares) Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable options, vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price [Roll forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, weighted average exercise price, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Unvested options forfeited, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Vested options expired, weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price, end of period (in dollars per share) Vested at end of period, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock options, additional disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Outstanding Options, weighted average remaining contractual term (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Vested at end of period, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested at end of period, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested or expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercised options, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Exercise Price Range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise Price Range, upper range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Number of outstanding options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Outstanding Options, weighted average remaining contractual term (in years) Outstanding Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Number of exercisable options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercisable Options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Contractual Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Tax benefit Income Tax Expense (Benefit) Gain on divestiture Total gain on disposition Gain (Loss) On Disposition Of Business, Including Income Tax Benefit Gain (Loss) On Disposition Of Business, Including Income Tax Benefit Estimated annual lease, royalty, and employment agreement expenses [Abstract] Contractual Obligation, Fiscal Year Maturity [Abstract] 2018 Contractual Obligation, Due in Next Fiscal Year 2019 Contractual Obligation, Due in Second Year 2020 Contractual Obligation, Due in Third Year 2021 Contractual Obligation, Due in Fourth Year 2022 Contractual Obligation, Due in Fifth Year Thereafter Contractual Obligation, Due after Fifth Year Total Contractual commitments Contractual Obligation Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Estimated future amortization expense [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2017 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net book value Finite-Lived Intangible Assets, Net Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Summary of Assets Transferred and Consideration Received Disposal Groups, Including Discontinued Operations [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net Accounts Receivable, Net, Current Inventory, net Inventory, Net Prepaid expenses Prepaid Expense and Other Assets, Current Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net of accumulated depreciation Property, Plant and Equipment, Net Intangible assets, net of accumulated amortization Deferred tax asset, net Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Current portion of earn out liability Business Combination, Contingent Consideration, Liability, Current Income taxes Accrued Income Taxes, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Earn out liability Business Combination, Contingent Consideration, Liability, Noncurrent Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 12) Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Preferred Stock, Value, Issued Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 111,035,248 outstanding at September 30, 2017 and 110,212,547 issued and 109,862,787 outstanding at December 31, 2016 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost: 1,668,678 shares at September 30, 2017 and 349,760 shares at December 31, 2016 Treasury Stock, Value Accumulated earnings (deficit) Retained Earnings (Accumulated Deficit) Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Accounts Receivable and Notes Receivable Receivables, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Recently Issued and Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Income Statement [Abstract] Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross margin Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development expenses Research and Development Expense Selling, general and administrative expenses Selling, General and Administrative Expense Operating income Operating Income (Loss) Other income (expense) Nonoperating Income (Expense) [Abstract] Interest expense, net Other Nonoperating Income (Expense) Income before income tax provision Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax provision (expense) benefit Net income Net income per common share - basic (in dollars per share) Earnings Per Share, Basic Net income per common share - diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity (up to) Line of Credit Facility, Maximum Borrowing Capacity Uncommitted incremental facility (up to) Line of Credit Facility, Uncommitted Incremental Facility Line of Credit Facility, Uncommitted Incremental Facility Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt issuance costs Debt Issuance Costs, Net Outstanding line of credit Long-term Line of Credit Intangible Assets and Royalty Agreement Intangible Assets Disclosure [Text Block] Number of business segments (segment) Number of Operating Segments Intangible Assets Activity Summary Schedule of Intangible assets activity [Table Text Block] Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for doubtful accounts Allowance for Doubtful Accounts [Member] Allowance for sales returns, discounts and allowances Allowance for Sales Returns [Member] Allowance for obsolescence Allowance for Obsolescence [Member] Allowance for Obsolescence [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period Valuation Allowances and Reserves, Balance Additions charged to Expense or Revenue Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Deductions and write-offs Valuation Allowances and Reserves, Deductions Balance at End of Period Income Tax Disclosure [Abstract] Income taxes Income Tax Disclosure [Text Block] Stockholders' equity: Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Loss Contingencies Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Bone Bank Action Bone Bank Action [Member] Bone Bank Action [Member] Liventa Action, 701 Patent Liventa Action, 701 Patent [Member] Liventa Action, 701 Patent [Member] Liventa Action, 437 Patent Liventa Action, 437 Patent [Member] Liventa Action, 437 Patent [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Lease expiration period Lessee, Operating Lease, Term of Contract Rent expense Operating Leases, Rent Expense Standby letters of credit Letters of Credit Outstanding, Amount Number of patent challenged grounds (claim) Loss Contingency, Pending Claims, Number Opinion allowing a review of patent (claim) Loss Contingency, Pending Claims, Allowed for Review, Number Loss Contingency Pending Claims Number Allowed for Review Income Tax Contingency [Table] Income Tax Contingency [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Forecast Scenario, Forecast [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Effective income tax rate reconciliation, discrete items related to divestiture Effective Income Tax Rate Reconciliation, Disposition of Business, Amount Effective income tax rate reconciliation, excess tax benefit Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Effective tax rate, related to divestiture Effective Income Tax Rate Reconciliation, Disposition of Business, Percent Inventory Schedule of Inventory, Current [Table Text Block] Distribution Agreement Distribution Rights [Member] Intangible assets acquired Eliminated accumulated depreciation expense Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Lab and clean room equipment Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, gross Inventory, Gross Reserve for obsolescence Inventory Valuation Reserves Inventory, net Class of Treasury Stock [Table] Class of Treasury Stock [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Authorized share amount for repurchase (up to) Stock Repurchase Program, Authorized Amount Shares repurchased, value Payments for Repurchase of Common Stock Brokerage commissions Treasury Stock, Brokerage Commissions Treasury Stock, Brokerage Commissions Remaining authorizations under the repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount Shares reissued from the treasury (in shares) Stock Issued During Period, Shares, Treasury Stock Reissued Shares reissued from the treasury, value Stock Issued During Period, Value, Treasury Stock Reissued Assets Held under Capital Leases Assets Held under Capital Leases [Member] Leasehold Improvements Paid by Others Leasehold Improvements Paid by Others [Member] Leasehold Improvements Paid by Others [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Capital Lease Obligations Capital Lease Obligations [Member] Capital leases interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Property plant and equipment sold in divestiture Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Patents Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Earnings Per Share [Abstract] Net Income Per Share Earnings Per Share [Text Block] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Consultant Consultant [Member] Consultant [Member] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted stock awards Restricted Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, Beginning Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, Ending Balance (in shares) Weighted- Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, Beginning Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, Ending Balance (in dollars per share) Total unrecognized stock-based compensation related to time-based, nonvested restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expenses expected to be recognized over a weighted-average period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Compensation [Abstract] Share-based Compensation [Abstract] Share-based compensation expense Allocated Share-based Compensation Expense Computation of basic and diluted net loss per share [Abstract] Computation of basic and diluted net loss per share [Abstract] -- None. No documentation exists for this element. -- Net income Denominator for basic earnings per share - weighted average shares (in shares) Effect of dilutive securities: Stock options and restricted stock outstanding (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) Income per common share - basic (in dollars per share) Income per common share - diluted (in dollars per share) Summary of Antidilutive Securities [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding stock options Employee Stock Option [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Computation of Basic and Diluted Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Supplemental disclosure of cash flow and non-cash investing and financing activities Cash Flow, Supplemental Disclosures [Text Block] EX-101.PRE 11 mdxg-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2017
Oct. 13, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name MIMEDX GROUP, INC.  
Entity Central Index Key 0001376339  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   111,034,873
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q3  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2017  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 36,522 $ 34,391
Accounts receivable, net 59,581 67,151
Inventory, net 10,419 17,814
Prepaid expenses 6,662 5,894
Other current assets 926 1,288
Total current assets 114,110 126,538
Property and equipment, net of accumulated depreciation 13,264 13,786
Goodwill 19,894 20,203
Intangible assets, net of accumulated amortization 10,377 23,268
Deferred tax asset, net 17,671 9,114
Other assets 3,391 354
Total assets 178,707 193,263
Current liabilities:    
Accounts payable 8,767 11,436
Accrued compensation 15,092 12,365
Accrued expenses 8,613 10,941
Current portion of earn out liability 0 8,740
Income taxes 2,329 5,768
Other current liabilities 358 1,482
Total current liabilities 35,159 50,732
Earn out liability 0 8,710
Other liabilities 1,076 821
Total liabilities 36,235 60,263
Commitments and contingencies (Note 12)
Stockholders' equity:    
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding 0 0
Common stock; $.001 par value; 150,000,000 shares authorized; 112,703,926 issued and 111,035,248 outstanding at September 30, 2017 and 110,212,547 issued and 109,862,787 outstanding at December 31, 2016 112 110
Additional paid-in capital 163,446 161,261
Treasury stock at cost: 1,668,678 shares at September 30, 2017 and 349,760 shares at December 31, 2016 (24,784) (2,216)
Accumulated earnings (deficit) 3,698 (26,155)
Total stockholders' equity 142,472 133,000
Total liabilities and stockholders' equity $ 178,707 $ 193,263
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2017
Dec. 31, 2016
Stockholders' equity:    
Preferred stock par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 112,703,926 110,212,547
Common stock, shares outstanding (in shares) 111,035,248 109,862,787
Treasury stock, shares (in shares) 1,668,678 349,760
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Net sales $ 84,573 $ 64,429 $ 233,592 $ 175,139
Cost of sales 9,599 7,997 26,972 23,338
Gross margin 74,974 56,432 206,620 151,801
Operating expenses:        
Research and development expenses 5,481 2,919 14,430 8,582
Selling, general and administrative expenses 60,233 48,179 168,498 131,599
Amortization of intangible assets 418 631 1,451 1,889
Operating income 8,842 4,703 22,241 9,731
Other income (expense)        
Gain on divestiture 4,274 0 4,274 0
Interest expense, net (43) (87) (337) (254)
Income before income tax provision 13,073 4,616 26,178 9,477
Income tax provision (expense) benefit 4,384 (1,295) 3,675 (2,984)
Net income $ 17,457 $ 3,321 $ 29,853 $ 6,493
Net income per common share - basic (in dollars per share) $ 0.16 $ 0.03 $ 0.28 $ 0.06
Net income per common share - diluted (in dollars per share) $ 0.15 $ 0.03 $ 0.26 $ 0.06
Weighted average shares outstanding - basic (in shares) 106,871,436 105,991,990 106,469,278 105,927,890
Weighted average shares outstanding - diluted (in shares) 117,501,925 112,361,179 116,547,006 112,193,701
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Earnings (Deficit)
Balance (in shares) at Dec. 31, 2016   110,212,547   349,760  
Balance, beginning of period at Dec. 31, 2016 $ 133,000 $ 110 $ 161,261 $ (2,216) $ (26,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Share-based compensation expense $ 15,232   15,232    
Exercise of stock options (in shares) 2,417,769 1,097,933   (1,319,836)  
Exercise of stock options $ 11,590 $ 1 (2,697) $ 14,286  
Issuance of restricted stock (in shares)   1,393,446   (1,630,093)  
Issuance of restricted stock 0 $ 1 (13,108) $ 13,107  
Restricted stock shares canceled/forfeited 0   2,717 $ (2,717)  
Restricted stock shares cancelled/forfeited (in shares)       283,198  
Shares issued for services performed $ 166   41 $ 125  
Shares issued for services performed (in shares) (17,539)     (17,539)  
Share repurchase (in shares)       3,644,327  
Share repurchase $ (44,032)     $ (44,032)  
Shares repurchased for tax withholding (in shares)       358,861  
Shares repurchased for tax withholding (3,337)     $ (3,337)  
Net income 29,853       29,853
Balance (in shares) at Sep. 30, 2017   112,703,926   1,668,678  
Balance, end of period at Sep. 30, 2017 $ 142,472 $ 112 $ 163,446 $ (24,784) $ 3,698
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net income $ 29,853 $ 6,493
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation 3,074 2,394
Amortization of intangible assets 1,451 1,889
Amortization of inventory fair value step-up 203 1,471
Amortization of deferred financing costs 135 136
Impairment of intangible assets 357 0
Share-based compensation 15,232 13,826
Change in deferred income taxes (8,557) (449)
Gain on divestiture (4,274) 0
Increase (decrease) in cash, net of effects of acquisition and divestiture, resulting from changes in:    
Accounts receivable 5,165 (7,671)
Inventory 3,738 (3,599)
Prepaid expenses (792) (2,023)
Other assets (402) 286
Accounts payable 478 (3,941)
Accrued compensation 2,873 (4,223)
Accrued expenses (2,228) 2,020
Income taxes (3,438) 2,621
Other liabilities (794) (82)
Net cash flows from operating activities 42,074 9,148
Cash flows from investing activities:    
Purchases of equipment (3,998) (5,301)
Stability acquisition 0 (7,631)
Fixed maturity securities redemption 0 3,000
Patent application costs (144) (515)
Net cash flows from investing activities (4,142) (10,447)
Cash flows from financing activities:    
Proceeds from exercise of stock options 11,590 2,548
Share repurchase under repurchase plan (44,032) (10,378)
Share repurchase for tax withholdings on vesting of restricted stock (3,337) (892)
Deferred financing costs 0 (106)
Payments under capital lease obligations (22) (21)
Net cash flows from financing activities (35,801) (8,849)
Net change in cash 2,131 (10,148)
Cash and cash equivalents, beginning of period 34,391 28,486
Cash and cash equivalents, end of period $ 36,522 $ 18,338
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation
 9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three and nine months ended September 30, 2017 and 2016, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2016, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 1, 2017. 
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® and EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; and Placental Collagen family with CollaFix® and AmnioFill® brands. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft;  EpiCord and AmnioCord are derived from the umbilical cord; and CollaFix® is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair and is in development. (Our former Physio product is owned by our former subsidiary, Stability Biologics, LLC which we divested effective September 30, 2017). See Note 3, Divestiture of Stability Biologics, LLC, below.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Please see Note 2 to the Company's Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2016, for a description of all significant accounting policies. 
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Notes Receivable
The Company's notes receivable as of September 30, 2017 are included in Other Assets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories are valued at the lower of cost or market, using the first-in, first-out ("FIFO") method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S., and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our customers and stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, were historically made through a distributor relationship with AvKARE Inc., which is a veteran-owned General Services Administration Federal Supply Schedule contractor. The Company's agreement with AvKARE expired on June 30, 2017. Upon expiration of the agreement, the Company had an obligation to repurchase AvKARE’s remaining inventory within 90 days in accordance with the terms of the agreement. As of September 30, 2017, the Company has satisfied the repurchase obligation.
A portion of the Company’s revenue is generated from consignment inventory maintained at hospitals or physicians' offices. Significant terms of our consignment agreements state that title to the inventory remains with the Company until the product, which has been segregated by the consignee, is withdrawn and therefore purchased by the consignee. The consignee accepts all risk of loss and full responsibility for any product in the consignment inventory that may be opened, lost, stolen or damaged. The Company recognizes revenue when we are notified that product has been used or implanted.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements. These estimates have historically been materially consistent with actual results.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their creditworthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. 
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes, after the measurement period has expired, to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible Assets in the Condensed Consolidated Balance Sheets. The Company capitalized approximately $144,000 of patent costs during the first nine months of 2017. The Company capitalized approximately $515,000 of patent costs during the first nine months of 2016.

Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued and Adopted Accounting Standards
The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. We are in the process of completing our procedures for adoption of the standard. We have identified one revenue stream from our contracts with customers: product sales. Based upon the results of our work to date we have elected the modified retrospective method as we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)." The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," which simplifies several aspects of the accounting for share-based payment award transactions including (a) income tax consequences; (b) classification of awards as either debt or equity liabilities; and (c) classification on the statement of cash flows.  The amendments are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods.  The Company has adopted this ASU as of January 1, 2017. The primary amendment impacting the Company's financial statements is the requirement for excess tax benefits or shortfalls on the exercise of share-based compensation awards to be presented in income tax expense in the Consolidated Statements of Income during the period the award is exercised as opposed to being recorded in additional paid-in capital on the Consolidated Balance Sheets.  The excess tax benefit or shortfall is calculated as the difference between the fair value of the award on the date of exercise and the fair value of the award used to measure the expense to be recognized over the service period.  Changes are required to be applied prospectively to all excess tax benefits and deficiencies resulting from the exercise of awards after the date of adoption. The ASU requires a "modified retrospective" approach application for excess tax benefits that were not previously recognized in situations where the tax deduction did not reduce current taxes payable. For the three-month period ended September 30, 2017, the Company recorded an income tax benefit of $1,510,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $4,205,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. As the end result is dependent on the future value of the Company's stock as well as the timing of employee exercises, the amount of future impact cannot be quantified at this time. The Company has elected to continue to estimate forfeitures expected to occur to determine the share-based compensation expense.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-04,"Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment." The update eliminates Step 2 from the goodwill impairment test. This ASU is effective for fiscal years beginning after December 15, 2019. The amendments in this update should be applied on a prospective basis. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestiture of Stability Biologics, LLC
 9 Months Ended
Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Divestiture of Stability Biologics, LLC
of Stability Biologics, LLC

On September 30, 2017, we completed the previously announced divestiture (the “Stability Divestiture”) of our wholly-owned subsidiary, Stability Biologics, LLC, a Georgia limited liability company (successor-in-interest to Stability Inc., a Florida corporation) (“Stability LLC”), pursuant to the Membership Interest Purchase Agreement (“Agreement”) by and among the Company, Stability LLC, each person that, as of January 13, 2016, was a stockholder (the “Stockholders”) of Stability Inc., a Florida corporation and a predecessor-in-interest to Stability LLC ("Stability, Inc."), and Brian Martin, as stockholder representative, the terms of which were previously disclosed in the Current Report on Form 8-K dated August 18, 2017.

A summary of the assets divested and consideration received follows (in thousands):
 
 
September 30,
 
 
2017
Assets divested
 
 
Trade receivables
 
$
2,405

Inventories
 
2,800

Prepaid expenses and other assets
 
1,610

Goodwill (a)
 
309

Intangible assets
 
11,857

Property and equipment, net of accumulated depreciation
1,446

Total assets divested
 
20,427

 
 
 
Liabilities divested
 
 
Accounts payable and accrued liabilities
 
3,487

Total liabilities divested
 
3,487

 
 
 
Total net assets divested
 
$
16,940

 
 
 
Transaction costs
 
$
400

 
 
 
Consideration received
 
 
Non-trade receivable
 
150

Note receivable
 
3,190

Intangible assets
 
630

Extinguishment of earn out liability
 
17,644

Total consideration received
 
$
21,614

 
 
 
Gain on sale
 
$
4,274


(a) In accordance with ASC 350-20-35-52 when a portion of a reporting unit is disposed of, goodwill associated with that business shall be included in the carrying amount of the business in determining the gain on disposal. In accordance with ASC 350-20-35-53, the amount of goodwill to be included in that carrying amount shall be based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. Based on an estimated approximate fair value of Stability LLC compared to the business retained, approximately $300,000 out of the total goodwill of $20.2 million residing in the reporting unit was included in the carrying amount of the business sold.
 
The total gain on the Stability Divestiture of $10,011,000 is comprised of a pretax book gain of $4,274,000 and an associated tax benefit of $5,737,000, which consists principally of the write off of deferred tax liabilities related to Stability LLC.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following items as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30, 2017
 
December 31, 2016
Raw materials
$
690

 
$
1,148

Work in process
5,164

 
6,677

Finished goods
5,554

 
10,817

 Inventory, gross
11,408

 
18,642

Reserve for obsolescence
(989
)
 
(828
)
 Inventory, net
$
10,419

 
$
17,814
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment
 9 Months Ended
Sep. 30, 2017
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and Equipment 
Property and equipment consisted of the following as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30,
2017
 
December 31,
2016
Leasehold improvements
$
3,116

 
$
3,274

Lab and clean room equipment
9,316

 
8,666

Furniture and office equipment
9,203

 
7,051

Construction in progress
2,583

 
3,300

   Property and equipment, gross
24,218

 
22,291

Less accumulated depreciation
(10,954
)
 
(8,505
)
   Property and equipment, net
$
13,264

 
$
13,786



Included in net property and equipment is approximately $427,000 of equipment covered under capital leases. The corresponding liability of approximately $8,600 is included in other liabilities in the accompanying Condensed Consolidated Balance Sheets. The interest rate for the lease is approximately 12% with a maturity date of January 2018.
Also included in net property and equipment is approximately $1.0 million in leasehold improvements paid for by the landlord of the Company's main facility with a corresponding liability included in other liabilities which is amortized over the term of the lease.
Gross depreciation expense for the nine months ended September 30, 2017 and 2016, was approximately $3,074,000 and $2,394,000, respectively, and approximately $1,013,000 and $838,000 for the three months ended September 30, 2017 and 2016, respectively. For the three and nine months ended September 30, 2017 approximately $626,000 of accumulated depreciation expense and $2,000,000 in gross book value of property and equipment was eliminated in connection with the Stability Divestiture.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Royalty Agreement
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2017
 
December 31, 2016
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,009

 
$
1,399

Patents & Know-How (b) (c) (d)
19 years
 
8,712

 
14,839

Customer & Supplier Relationships (b) (d)
13 years
 
4,271

 
9,091

Tradenames & Trademarks (d)
indefinite
 
1,008

 
1,458

Non-compete agreements
4 years
 
120

 
830

In Process Research & Development (b)
various
 
25

 
25

Patents in Process (c)
various
 
1,742

 
2,618

Total
 
 
16,887

 
30,260

Less Accumulated amortization and impairment charges
 
 
(6,510
)
 
(6,992
)
Net
 
 
$
10,377

 
$
23,268

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of September 30, 2017, the license was fully amortized.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. For the nine months ended September 30, 2017, approximately $663,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.
(d)
On January 13, 2016, the Company acquired Stability, Inc. As a result, the Company recorded intangible assets for Patents & Know-How of $6,790,000, Customer & Supplier Relationships of $5,330,000, Non-compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.
On September 30, 2017, the Company completed the Stability Divestiture which resulted in the transfer of intangible assets acquired in 2016 and the acquisition of a Distribution Agreement valued at $510,000 and a Non-compete Agreement valued at $120,000.
Gross amortization expense for the nine months ended September 30, 2017 and 2016, was approximately $1,451,000 and $1,889,000, respectively, and $418,000 and $631,000 for the three months ended September 30, 2017 and 2016, respectively. For the three and nine months ended September 30, 2017, approximately $1,932,000 of accumulated amortization expense was eliminated in connection with the Stability Divestiture.
Expected future amortization of intangible assets as of September 30, 2017, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2017 (a)
$
237

2018
950

2019
950

2020
950

2021
942

Thereafter
5,340

 
$
9,369

(a) Estimated amortization expense for the year ending December 31, 2017, includes only amortization to be recorded after September 30, 2017.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Credit Facility
 9 Months Ended
Sep. 30, 2017
Debt Disclosure [Abstract]  
Credit Facility
Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. In September 2017, the expiration date of the credit agreement was extended to October 12, 2019. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. The obligations of the loan parties under the Credit Agreement and the other credit documents are secured by liens on and security interests in substantially all of the assets of each of the loan parties and a pledge of the equity interests of each subsidiary owned by a loan party, subject to certain customary exclusions. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the initial life of the facility. The Credit Agreement contains customary representations, warranties, covenants and events of default, including restrictions on certain payments of dividends by the Company. As of September 30, 2017, there were no outstanding revolving loans under the credit facility, and the Company was in compliance with all covenants under the Credit Agreement.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Share
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. 
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net income
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

Denominator for basic earnings per share - weighted average shares
106,871,436

 
105,991,990

 
106,469,278

 
105,927,890

Effect of dilutive securities: Stock options and restricted stock outstanding(a)
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
117,501,925

 
112,361,179

 
116,547,006

 
112,193,701

Income per common share - basic
$
0.16

 
$
0.03

 
$
0.28

 
$
0.06

Income per common share - diluted
$
0.15

 
$
0.03

 
$
0.26

 
$
0.06

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Outstanding stock options
7,916,564

 
5,704,112

 
7,985,521

 
5,767,469

Restricted stock awards
2,713,925

 
665,077

 
2,092,207

 
498,342

 
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Equity
Equity
Stock Incentive Plans 

The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.

Stock Options
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2017
12,552,608

 
$
3.61

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(2,417,769
)
 
$
4.80

 
 
 
 
Unvested options forfeited
(25,839
)
 
$
6.54

 
 
 
 
Vested options expired
(68,991
)
 
$
5.79

 
 
 
 

Outstanding at September 30, 2017
10,040,009

 
$
3.30

 
4.60
 
$
86,178,050

Vested at September 30, 2017
9,976,636

 
$
3.26

 
4.59
 
$
86,042,771

Vested or expected to vest at September 30, 2017 (a)
10,043,166

 
$
3.30

 
4.60
 
$
86,176,954

(a)
Includes forfeiture-adjusted unvested shares.
The intrinsic value of the options exercised during the nine months ended September 30, 2017, was approximately $17,994,945. 
Following is a summary of stock options outstanding and exercisable at September 30, 2017:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.70 - $1.09
1,094,429

 
2.8
 
$
0.91

 
1,094,429

 
$
0.91

$1.10 - $1.65
4,290,379

 
3.7
 
1.30

 
4,290,379

 
1.30

$2.45 - $3.75
854,001

 
5.0
 
2.77

 
854,001

 
2.77

$4.19 - $6.38
1,989,205

 
5.7
 
5.36

 
1,989,205

 
5.36

$6.49 - $9.78
1,713,328

 
6.4
 
7.30

 
1,683,625

 
7.26

$9.90 - $10.99
98,667

 
7.2
 
10.38

 
64,997

 
10.38

 
10,040,009

 
4.6
 
$
3.30

 
9,976,636

 
$
3.26

 
Total unrecognized compensation expense related to granted stock options at September 30, 2017, was approximately $98,900 and will be charged to expense ratably through January 2018. 
The fair value of options granted by the Company is estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method,” which computes expected term as the mid point between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company's lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
There were no options granted during the nine months ended September 30, 2017 and September 30, 2016.
Restricted Stock Awards                                                    
Activity with respect to restricted stock awards for the nine months ended September 30, 2017 is summarized as follows and includes 17,539 shares of common stock valued at approximately $166,000 which were issued under the 2016 Plan to a consultant in return for services performed: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2017
3,828,445

 
$8.53
Granted
3,041,078

 
9.23
Vested
(1,457,449
)
 
8.42
Forfeited
(283,198
)
 
8.67

Unvested at September 30, 2017
5,128,876

 
8.97

As of September 30, 2017, there was approximately $32,910,620 of total unrecognized share-based compensation expense related to time-based, nonvested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.04 years, which approximates the remaining vesting period of these grants. All shares noted above as unvested are considered issued and outstanding at September 30, 2017.
For the three and nine months ended September 30, 2017 and 2016, the Company recognized share-based compensation expense as follows (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Cost of sales
$
119

 
$
109

 
$
393

 
$
300

Research and development
148

 
159

 
425

 
520

Selling, general and administrative
5,039

 
4,433

 
14,414

 
13,006

 
$
5,306

 
$
4,701

 
$
15,232

 
$
13,826


Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. Our Board subsequently extended the program until December 31, 2017, and increased the total authorization to $120 million as of October 26, 2017. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the nine months ended September 30, 2017, the Company repurchased 3,644,327 shares of its common stock for a purchase price of approximately $43,923,000 before brokerage commissions of approximately $109,000. As of September 30, 2017, the Company had approximately $13,000 of availability remaining under the repurchase program. In addition, the Company repurchased 358,861 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock for the nine months ended September 30, 2017.
Additionally, for the nine months ended September 30, 2017, the Company reissued 2,684,270 shares from the treasury for restricted stock grants and stock option exercises, net of forfeitures, with an aggregate carrying value of approximately $24,801,000.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2017
Income Tax Disclosure [Abstract]  
Income taxes
Income Taxes 

The effective tax rate for the three months ended September 30, 2017 was (33.5)% and reflects discrete tax benefits related to the Stability Divestiture of $5,737,000, and $1,702,000 primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was 15.4% for the three months ended September 30, 2017 and 28.1% for the three months ended September 30, 2016, respectively.
The effective tax rate for the nine months ended September 30, 2017 was (14.0)% and reflects discrete tax benefits related to the Stability Divestiture of $5,737,000, and $5,618,000 primarily related to equity compensation deductions. The effective tax rate exclusive of the tax benefit associated with the Stability Divestiture was 9.4% for the nine months ended September 30, 2017 and 31.5% for the nine months ended September 30, 2016, respectively.
As of the end of September 2017, the projected annual effective tax rate for 2017 is 35.1% (excluding discrete items).
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
 9 Months Ended
Sep. 30, 2017
Supplemental Cash Flow Elements [Abstract]  
Supplemental disclosure of cash flow and non-cash investing and financing activities
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities:
    
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2017
 
2016
Cash paid for interest
$
119

 
$
118

Income taxes paid
8,289

 
637

Share issuance of 441,009 shares in connection with acquisition
—

 
3,346

Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively
166

 
346
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Commitments and Contingencies
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Contractual Commitments and Contingencies
Contractual Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted above in Note 5, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space.
The estimated annual lease payments, meeting space commitments are as follows (in thousands):
Twelve months ended September 30,
2018
$
2,634

2019
2,826

2020
1,707

2021
1,428

2022
1,470

Thereafter
495

 
$
10,560



Rent expense for the nine months ended September 30, 2017 and 2016, was approximately $1,244,000 and $1,311,000, respectively, and was approximately $403,000 and $453,000 for the three months ended September 30, 2017 and 2016, respectively, and is allocated among cost of sales, research and development and selling, general and administrative expenses.

Letters of Credit
As a condition of the lease for the Company's main facility, the Company is obligated under standby letters of credit in the amount of approximately $52,000.

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, the Company would need a biologics license to lawfully market those micronized products (the "Untitled Letter"). Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's micronized allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing human cells, tissues, and cellular and tissue-based products ("HCT/P") regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from the FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with current good manufacturing processes ("cGMP"). Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products.

Former Employee Litigation

On December 13, 2016, the Company filed lawsuits against former employees Jess Kruchoski (in the lawsuit styled MiMedx Group, Inc. v. Academy Medical, LLC, et. al. in the County Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the “Florida Action”)) and Luke Tornquist (in the lawsuit styled MiMedx Group, Inc., v. Luke Tornquist in the Superior Court for Cobb County, Georgia, which was removed to the United States District Court for the Northern District of Georgia (the “Georgia Action”)).  Both the Florida and Georgia Actions assert claims against Messrs. Kruchoski and Tornquist that each of them violated their restrictive covenants entered into with the Company, that each of them misappropriated trade secrets of the Company, that each of them tortiously interfered with contracts between the Company and its customers and employees and that each of them breached his duty of loyalty owed to the Company, among other claims. The Company sought injunctive relief against each of Mr. Kruchoski and Tornquist to enforce its restrictive covenants in place with each of them. The Company obtained consent injunctions from each party enforcing those covenants. The Company is also seeking monetary damages in an amount to be determined at trial.

The Company continues to vigorously pursue its claims asserted in all of these actions and also to vigorously defend against the lawsuits and counterclaims asserted against it.

Patent Litigation

The Company continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. (formerly known as AFCell Medical, Inc.) ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of the Company's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached a settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

The Company asserts that Liventa, Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. Trial has been set for the week of January 22, 2018.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. On September 7, 2017, the Court granted partial summary judgment in defendants’ favor on a portion of the claim. The Company filed a motion for reconsideration on October 4, 2017.





The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "'494" patent). Vivex answered the Company’s complaint and filed counterclaims of non-infringement and invalidity. On January 4, 2017, the Court granted a joint motion to stay the proceedings pending the outcome of the Bone Bank Action.

IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review ("IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "'687" patent) and the '494 patent, while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. The Company decided not to appeal the decision, as it impacted a non-core patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable.  The Company filed an appeal of the PTAB’s decision regarding the '437 patent. On September 14, 2017, the Federal Circuit affirmed the PTAB’s decision regarding the ‘437 patent.


Other Litigation

The Capitol Forum Litigation

On September 21, 2017, MiMedx filed a lawsuit against DBW Partners LLC d/b/a The Capitol Forum (the “Capitol Forum”), Trevor Baine, Teddy Downey, Jake Williams, Miles Pulsford, Matt Treacy and John Does 1-100 (collectively, the “Capitol Defendants”) in the United States District Court for the District of Columbia. The Company has brought claims for defamation, libel, slander, tortious interference, false light, and violations of the Lanham Act in relation to the Capitol Defendants publishing articles and sending emails to shareholders that are false and misleading for the purpose of negatively impacting the price of MiMedx stock. The Capitol Defendants have not yet responded to the Company’s complaint.

The Aurelius Value and Viceroy Litigation

On October 4, 2017, the Company and Sean McCormack (a Company employee) filed a lawsuit against Sparrow Fund Management LP a/k/a Aurelius Value, Viceroy Research, John Fichthorn, BR Dialectic Capital Management LLC and John Does 1-10 in the United States District Court for the Southern District of New York asserting claims for libel, slander, defamation, false light and tortious interference based on false and misleading “research” reports and other false and misleading statements allegedly published in order to manipulate the Company's stock. Defendants Sparrow, Fichthorn, and BR Dialectic have filed motions to dismiss MiMedx’s complaint which are pending before the court.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Schedule II - Valuation and Qualifying Accounts
 9 Months Ended
Sep. 30, 2017
Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
 Three and Nine Months Ended September 30, 2017 and 2016 (in thousands)
 
 
 
 
 
 
 
 
Balance at
Beginning of Period
Additions charged to Expense or Revenue
Deductions
and write-offs
Balance at
End of Period
 
 
 
 
 
 
For the three months ended September 30, 2017
 
 
 
 
 
Allowance for doubtful accounts
 
$
7,219

$
150

$
(409
)
$
6,960

Allowance for sales returns, discounts and allowances
 
3,461

1,288

(1,270
)
3,479

Allowance for obsolescence
 
1,113

212

(336
)
989

 
 
 
 
 
 
For the three months ended September 30, 2016
 
 
 
 
 
Allowance for doubtful accounts
 
$
4,086

$
800

$
(536
)
$
4,350

Allowance for sales returns, discounts and allowances
 
2,191

2,591

(2,520
)
2,262

Allowance for obsolescence
 
1,780

339

(1,411
)
708

 
 
 
 
 
 
For the nine months ended September 30, 2017
 
 
 
 
 
Allowance for doubtful accounts
 
$
4,842

$
2,600

$
(482
)
$
6,960

Allowance for sales returns, discounts and allowances
 
4,894

5,794

(7,209
)
3,479

Allowance for obsolescence
 
828

953

(792
)
989

 
 
 
 
 
 
For the nine months ended September 30, 2016
 
 
 
 
 
Allowance for doubtful accounts
 
$
3,270

$
1,635

$
(555
)
$
4,350

Allowance for sales returns, discounts and allowances
 
1,262

5,917

(4,917
)
2,262

Allowance for obsolescence
 
397

1,910

(1,599
)
708
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) from interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASU’’) to the FASB’s Accounting Standards Codification (“ASC”).  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included.  Operating results for the three and nine months ended September 30, 2017 and 2016, are not necessarily indicative of the results that may be expected for the fiscal year.  The balance sheet at December 31, 2016, has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. 
You should read these condensed consolidated financial statements together with the historical consolidated financial statements of the Company for the year ended December 31, 2016, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 1, 2017. 
Segment Reporting
The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. 
Accounts Receivable and Notes Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. 
Notes Receivable
The Company's notes receivable as of September 30, 2017 are included in Other Assets and were valued taking into consideration cost of the market participant inputs, market conditions, liquidity, operating results and other qualitative factors.
Inventories
Inventories
Inventories are valued at the lower of cost or market, using the first-in, first-out ("FIFO") method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes until the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third party representatives in the U.S., and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our customers and stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, were historically made through a distributor relationship with AvKARE Inc., which is a veteran-owned General Services Administration Federal Supply Schedule contractor. The Company's agreement with AvKARE expired on June 30, 2017. Upon expiration of the agreement, the Company had an obligation to repurchase AvKARE’s remaining inventory within 90 days in accordance with the terms of the agreement. As of September 30, 2017, the Company has satisfied the repurchase obligation.
A portion of the Company’s revenue is generated from consignment inventory maintained at hospitals or physicians' offices. Significant terms of our consignment agreements state that title to the inventory remains with the Company until the product, which has been segregated by the consignee, is withdrawn and therefore purchased by the consignee. The consignee accepts all risk of loss and full responsibility for any product in the consignment inventory that may be opened, lost, stolen or damaged. The Company recognizes revenue when we are notified that product has been used or implanted.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements. These estimates have historically been materially consistent with actual results.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their creditworthiness, and current economic conditions. We only record revenue when collectability is reasonably assured.
Acquisitions
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date.

Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes, after the measurement period has expired, to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of an earn out based on sales less direct production costs, and are valued using discounted cash flow techniques. The fair value of these payments is based upon probability-weighted future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payments changes.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue-based products and processes. The Company capitalizes such costs as patents in progress until a patent is obtained. When a patent is issued, the costs are amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. If a patent is not obtained, costs are expensed. Patents are included in Intangible Assets in the Condensed Consolidated Balance Sheets.
Treasury Stock
Treasury Stock
The Company accounts for the purchase of treasury stock under the cost method. Treasury stock which is reissued for the exercise of option grants and the issuance of restricted stock grants is accounted for on a FIFO basis.
Recently Issued and Adopted Accounting Standards
Recently Issued and Adopted Accounting Standards
The Company considers the applicability and impact of all ASUs issued, both effective and not yet effective. In May 2014, the FASB issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. We are in the process of completing our procedures for adoption of the standard. We have identified one revenue stream from our contracts with customers: product sales. Based upon the results of our work to date we have elected the modified retrospective method as we currently do not expect the application of the new standard to these contracts to have a material impact to our consolidated financial statements either at initial implementation or on an ongoing basis.

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)." The core principle of Topic 842 is that a lessee
should recognize the assets and liabilities that arise from both capital and operating leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting," which simplifies several aspects of the accounting for share-based payment award transactions including (a) income tax consequences; (b) classification of awards as either debt or equity liabilities; and (c) classification on the statement of cash flows.  The amendments are effective for public business entities for annual periods beginning after December 15, 2016, and interim periods within those annual periods.  The Company has adopted this ASU as of January 1, 2017. The primary amendment impacting the Company's financial statements is the requirement for excess tax benefits or shortfalls on the exercise of share-based compensation awards to be presented in income tax expense in the Consolidated Statements of Income during the period the award is exercised as opposed to being recorded in additional paid-in capital on the Consolidated Balance Sheets.  The excess tax benefit or shortfall is calculated as the difference between the fair value of the award on the date of exercise and the fair value of the award used to measure the expense to be recognized over the service period.  Changes are required to be applied prospectively to all excess tax benefits and deficiencies resulting from the exercise of awards after the date of adoption. The ASU requires a "modified retrospective" approach application for excess tax benefits that were not previously recognized in situations where the tax deduction did not reduce current taxes payable. For the three-month period ended September 30, 2017, the Company recorded an income tax benefit of $1,510,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. For the nine months ended September 30, 2017, the Company recorded an income tax benefit of $4,205,000 related to the excess tax benefit of exercised awards during the period, that would have been recorded in additional paid-in capital during prior years. As the end result is dependent on the future value of the Company's stock as well as the timing of employee exercises, the amount of future impact cannot be quantified at this time. The Company has elected to continue to estimate forfeitures expected to occur to determine the share-based compensation expense.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-04,"Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment." The update eliminates Step 2 from the goodwill impairment test. This ASU is effective for fiscal years beginning after December 15, 2019. The amendments in this update should be applied on a prospective basis. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the nine months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, restricted stock and warrants using the treasury stock method. 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestiture of Stability Biologics, LLC (Tables)
 9 Months Ended
Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Summary of Assets Transferred and Consideration Received
A summary of the assets divested and consideration received follows (in thousands):
 
 
September 30,
 
 
2017
Assets divested
 
 
Trade receivables
 
$
2,405

Inventories
 
2,800

Prepaid expenses and other assets
 
1,610

Goodwill (a)
 
309

Intangible assets
 
11,857

Property and equipment, net of accumulated depreciation
1,446

Total assets divested
 
20,427

 
 
 
Liabilities divested
 
 
Accounts payable and accrued liabilities
 
3,487

Total liabilities divested
 
3,487

 
 
 
Total net assets divested
 
$
16,940

 
 
 
Transaction costs
 
$
400

 
 
 
Consideration received
 
 
Non-trade receivable
 
150

Note receivable
 
3,190

Intangible assets
 
630

Extinguishment of earn out liability
 
17,644

Total consideration received
 
$
21,614

 
 
 
Gain on sale
 
$
4,274


(a) In accordance with ASC 350-20-35-52 when a portion of a reporting unit is disposed of, goodwill associated with that business shall be included in the carrying amount of the business in determining the gain on disposal. In accordance with ASC 350-20-35-53, the amount of goodwill to be included in that carrying amount shall be based on the relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. Based on an estimated approximate fair value of Stability LLC compared to the business retained, approximately $300,000 out of the total goodwill of $20.2 million residing in the reporting unit was included in the carrying amount of the business sold.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2017
Inventory Disclosure [Abstract]  
Inventory
Inventories consisted of the following items as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30, 2017
 
December 31, 2016
Raw materials
$
690

 
$
1,148

Work in process
5,164

 
6,677

Finished goods
5,554

 
10,817

 Inventory, gross
11,408

 
18,642

Reserve for obsolescence
(989
)
 
(828
)
 Inventory, net
$
10,419

 
$
17,814
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2017
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment
Property and equipment consisted of the following as of September 30, 2017, and December 31, 2016 (in thousands):
 
September 30,
2017
 
December 31,
2016
Leasehold improvements
$
3,116

 
$
3,274

Lab and clean room equipment
9,316

 
8,666

Furniture and office equipment
9,203

 
7,051

Construction in progress
2,583

 
3,300

   Property and equipment, gross
24,218

 
22,291

Less accumulated depreciation
(10,954
)
 
(8,505
)
   Property and equipment, net
$
13,264

 
$
13,786
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Royalty Agreement (Tables)
 9 Months Ended
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Activity Summary
Intangible assets are summarized as follows (in thousands):
 
Weighted
Average
Amortization
Lives
 
September 30, 2017
 
December 31, 2016
 
 
 
Cost
 
Cost
Licenses (a) (b) (c) (d)
7 years
 
$
1,009

 
$
1,399

Patents & Know-How (b) (c) (d)
19 years
 
8,712

 
14,839

Customer & Supplier Relationships (b) (d)
13 years
 
4,271

 
9,091

Tradenames & Trademarks (d)
indefinite
 
1,008

 
1,458

Non-compete agreements
4 years
 
120

 
830

In Process Research & Development (b)
various
 
25

 
25

Patents in Process (c)
various
 
1,742

 
2,618

Total
 
 
16,887

 
30,260

Less Accumulated amortization and impairment charges
 
 
(6,510
)
 
(6,992
)
Net
 
 
$
10,377

 
$
23,268

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of September 30, 2017, the license was fully amortized.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. For the nine months ended September 30, 2017, approximately $663,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.
(d)
On January 13, 2016, the Company acquired Stability, Inc. As a result, the Company recorded intangible assets for Patents & Know-How of $6,790,000, Customer & Supplier Relationships of $5,330,000, Non-compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.
Estimated Future Amortization Expense for Intangible Assets
Expected future amortization of intangible assets as of September 30, 2017, is as follows (in thousands):
Year ending December 31,
Estimated
Amortization
Expense
2017 (a)
$
237

2018
950

2019
950

2020
950

2021
942

Thereafter
5,340

 
$
9,369

(a) Estimated amortization expense for the year ending December 31, 2017, includes only amortization to be recorded after September 30, 2017.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Share (Tables)
 9 Months Ended
Sep. 30, 2017
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss per Share
The following table sets forth the computation of basic and diluted net income per share (in thousands except share data):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Net income
$
17,457

 
$
3,321

 
$
29,853

 
$
6,493

Denominator for basic earnings per share - weighted average shares
106,871,436

 
105,991,990

 
106,469,278

 
105,927,890

Effect of dilutive securities: Stock options and restricted stock outstanding(a)
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
117,501,925

 
112,361,179

 
116,547,006

 
112,193,701

Income per common share - basic
$
0.16

 
$
0.03

 
$
0.28

 
$
0.06

Income per common share - diluted
$
0.15

 
$
0.03

 
$
0.26

 
$
0.06

(a) Securities outstanding that are included in the computation above, utilizing the treasury stock method are as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Outstanding stock options
7,916,564

 
5,704,112

 
7,985,521

 
5,767,469

Restricted stock awards
2,713,925

 
665,077

 
2,092,207

 
498,342

 
10,630,489

 
6,369,189

 
10,077,728

 
6,265,811
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity (Tables)
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Stock Options Activity
Activity with respect to the stock options is summarized as follows:
 
Number
 of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2017
12,552,608

 
$
3.61

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(2,417,769
)
 
$
4.80

 
 
 
 
Unvested options forfeited
(25,839
)
 
$
6.54

 
 
 
 
Vested options expired
(68,991
)
 
$
5.79

 
 
 
 

Outstanding at September 30, 2017
10,040,009

 
$
3.30

 
4.60
 
$
86,178,050

Vested at September 30, 2017
9,976,636

 
$
3.26

 
4.59
 
$
86,042,771

Vested or expected to vest at September 30, 2017 (a)
10,043,166

 
$
3.30

 
4.60
 
$
86,176,954

(a)
Includes forfeiture-adjusted unvested shares.
Stock Options Outstanding and Exercisable
Following is a summary of stock options outstanding and exercisable at September 30, 2017:
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
Number outstanding
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Weighted-
Average
Exercise
Price
 
Number Exercisable
 
Weighted-
Average
Exercise Price
$0.70 - $1.09
1,094,429

 
2.8
 
$
0.91

 
1,094,429

 
$
0.91

$1.10 - $1.65
4,290,379

 
3.7
 
1.30

 
4,290,379

 
1.30

$2.45 - $3.75
854,001

 
5.0
 
2.77

 
854,001

 
2.77

$4.19 - $6.38
1,989,205

 
5.7
 
5.36

 
1,989,205

 
5.36

$6.49 - $9.78
1,713,328

 
6.4
 
7.30

 
1,683,625

 
7.26

$9.90 - $10.99
98,667

 
7.2
 
10.38

 
64,997

 
10.38

 
10,040,009

 
4.6
 
$
3.30

 
9,976,636

 
$
3.26
Restricted Stock Awards Roll Forward
Activity with respect to restricted stock awards for the nine months ended September 30, 2017 is summarized as follows and includes 17,539 shares of common stock valued at approximately $166,000 which were issued under the 2016 Plan to a consultant in return for services performed: 
 
Number
of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2017
3,828,445

 
$8.53
Granted
3,041,078

 
9.23
Vested
(1,457,449
)
 
8.42
Forfeited
(283,198
)
 
8.67

Unvested at September 30, 2017
5,128,876

 
8.97
Allocation of Share-based Compensation
For the three and nine months ended September 30, 2017 and 2016, the Company recognized share-based compensation expense as follows (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2017
 
2016
 
2017
 
2016
Cost of sales
$
119

 
$
109

 
$
393

 
$
300

Research and development
148

 
159

 
425

 
520

Selling, general and administrative
5,039

 
4,433

 
14,414

 
13,006

 
$
5,306

 
$
4,701

 
$
15,232

 
$
13,826
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)
 9 Months Ended
Sep. 30, 2017
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):
 
Nine Months Ended September 30,
 
2017
 
2016
Cash paid for interest
$
119

 
$
118

Income taxes paid
8,289

 
637

Share issuance of 441,009 shares in connection with acquisition
—

 
3,346

Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively
166

 
346
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Estimated Annual Lease, Royalty and Employment Agreement Expenses
The estimated annual lease payments, meeting space commitments are as follows (in thousands):
Twelve months ended September 30,
2018
$
2,634

2019
2,826

2020
1,707

2021
1,428

2022
1,470

Thereafter
495

 
$
10,560
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation (Details)
 9 Months Ended
Sep. 30, 2017
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of business segments (segment) 1
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Finite-Lived Intangible Assets [Line Items]        
Effective income tax rate reconciliation, excess tax benefit $ 1,702 $ 1,510 $ 5,618 $ 4,205
Patents        
Finite-Lived Intangible Assets [Line Items]        
Intangible assets, net of accumulated amortization     $ 144 $ 515
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestiture of Stability Biologics, LLC - Summary of Assets Transferred and Consideration Received (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Consideration received            
Gain on sale   $ 4,274 $ 0 $ 4,274 $ 0  
Goodwill $ 19,894 19,894   19,894   $ 20,203
Stability Biologics, LLC | Disposal Group, Disposed of by Sale, Not Discontinued Operations            
Assets divested            
Trade receivables 2,405 2,405   2,405    
Inventories 2,800 2,800   2,800    
Prepaid expenses and other assets 1,610 1,610   1,610    
Goodwill 309 309   309    
Intangible assets 11,857 11,857   11,857    
Property and equipment, net of accumulated depreciation 1,446 1,446   1,446    
Total assets divested 20,427 20,427   20,427    
Liabilities divested            
Accounts payable and accrued liabilities 3,487 3,487   3,487    
Total liabilities divested 3,487 3,487   3,487    
Total net assets divested 16,940 $ 16,940   $ 16,940    
Transaction costs 400          
Consideration received            
Non-trade receivable 150          
Note receivable 3,190          
Intangible assets 630          
Extinguishment of earn out liability 17,644          
Total consideration received 21,614          
Gain on sale $ 4,274          
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestiture of Stability Biologics, LLC - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Tax benefit   $ 4,384 $ (1,295) $ 3,675 $ (2,984)
Gain on divestiture   $ 4,274 $ 0 $ 4,274 $ 0
Stability Biologics, LLC | Disposal Group, Disposed of by Sale, Not Discontinued Operations          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Tax benefit $ 5,737        
Gain on divestiture 4,274        
Total gain on disposition $ 10,011        
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Inventory Disclosure [Abstract]    
Raw materials $ 690 $ 1,148
Work in process 5,164 6,677
Finished goods 5,554 10,817
Inventory, gross 11,408 18,642
Reserve for obsolescence (989) (828)
Inventory, net $ 10,419 $ 17,814
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 24,218 $ 22,291
Less accumulated depreciation (10,954) (8,505)
Property and equipment, net 13,264 13,786
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,116 3,274
Lab and clean room equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,316 8,666
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,203 7,051
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 2,583 $ 3,300
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 13,264,000   $ 13,264,000   $ 13,786,000
Other liabilities 1,076,000   1,076,000   $ 821,000
Depreciation 1,013,000 $ 838,000 3,074,000 $ 2,394,000  
Eliminated accumulated depreciation expense 626,000   626,000    
Property plant and equipment sold in divestiture $ 2,000,000   $ 2,000,000    
Capital Lease Obligations          
Property, Plant and Equipment [Line Items]          
Capital leases interest rate percentage 12.00%   12.00%    
Assets Held under Capital Leases          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 427,000   $ 427,000    
Other liabilities 8,600   8,600    
Leasehold Improvements Paid by Others          
Property, Plant and Equipment [Line Items]          
Property and equipment, net of accumulated depreciation $ 1,000,000   $ 1,000,000    
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) - USD ($)
 9 Months Ended
Jan. 29, 2007
Sep. 30, 2017
Dec. 31, 2016
Jan. 13, 2016
Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]          
Total   $ 16,887,000 $ 30,260,000    
Less Accumulated amortization and impairment charges   (6,510,000) (6,992,000)    
Net   10,377,000 23,268,000    
Tradenames & trademarks          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   1,008,000 1,458,000    
Tradenames & trademarks | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived       $ 450,000  
Tradenames & trademarks | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         $ 1,008,000
In process research & development          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   25,000 25,000    
In process research & development | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived         25,000
Patents in process          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value, indefinite lived   $ 1,742,000 2,618,000    
Licenses          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   7 years      
Gross carrying value   $ 1,009,000 1,399,000    
Licenses | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value       390,000  
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.          
Finite-Lived Intangible Assets [Line Items]          
Acquisition price $ 996,000        
Maximum time of approval 30 days        
Fair value of earn-out $ 200,000        
Contingent royalty to be paid to licensor 3.00%        
Annual royalty payment, minimum $ 50,000        
Licenses | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         13,000
Patents and know-how          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   19 years      
Gross carrying value   $ 8,712,000 14,839,000    
Patents and know-how | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value       6,790,000  
Patents and know-how | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         7,690,000
Finite lived intangible assets   $ 663,000      
Customer & supplier relationships          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   13 years      
Gross carrying value   $ 4,271,000 9,091,000    
Customer & supplier relationships | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value       5,330,000  
Customer & supplier relationships | Surgical Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value         $ 3,761,000
Non compete agreements          
Finite-Lived Intangible Assets [Line Items]          
Weighted average amortization lives   4 years      
Gross carrying value   $ 120,000 $ 830,000    
Non compete agreements | Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Gross carrying value       $ 830,000  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Royalty Agreement - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]          
Amortization of intangible assets $ 418 $ 631 $ 1,451 $ 1,889  
Eliminated accumulated depreciation expense 626   626    
Stability Biologics, LLC          
Finite-Lived Intangible Assets [Line Items]          
Eliminated accumulated depreciation expense 1,932   1,932    
Distribution Agreement          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets acquired 510   510    
Non compete agreements          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets acquired $ 120   $ 120   $ 830
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Sep. 30, 2017
USD ($)
Estimated future amortization expense [Abstract]  
2017 $ 237
2018 950
2019 950
2020 950
2021 942
Thereafter 5,340
Net book value $ 9,369
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Credit Facility (Details) - Credit Agreement - Revolving Credit Facility - USD ($)
Oct. 12, 2015
Sep. 30, 2017
Debt Instrument [Line Items]    
Maximum borrowing capacity (up to) $ 50,000,000  
Uncommitted incremental facility (up to) 35,000,000  
Debt issuance costs $ 500,000  
Outstanding line of credit   $ 0
London Interbank Offered Rate (LIBOR) | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate 1.50%  
London Interbank Offered Rate (LIBOR) | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate 2.25%  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Computation of basic and diluted net loss per share [Abstract]        
Net income $ 17,457 $ 3,321 $ 29,853 $ 6,493
Denominator for basic earnings per share - weighted average shares (in shares) 106,871,436 105,991,990 106,469,278 105,927,890
Effect of dilutive securities: Stock options and restricted stock outstanding (in shares) 10,630,489 6,369,189 10,077,728 6,265,811
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 117,501,925 112,361,179 116,547,006 112,193,701
Income per common share - basic (in dollars per share) $ 0.16 $ 0.03 $ 0.28 $ 0.06
Income per common share - diluted (in dollars per share) $ 0.15 $ 0.03 $ 0.26 $ 0.06
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 10,630,489 6,369,189 10,077,728 6,265,811
Outstanding stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 7,916,564 5,704,112 7,985,521 5,767,469
Restricted stock awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share (in shares) 2,713,925 665,077 2,092,207 498,342
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity - Stock Incentive Plans (Details)
 9 Months Ended
Sep. 30, 2017
USD ($)
plan
$ / shares
shares
Sep. 30, 2016
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of share-based compensation plans (plan) | plan 4  
Number of shares [Roll forward]    
Outstanding, beginning of period (in shares) | shares 12,552,608  
Granted (in shares) | shares 0 0
Exercised (in shares) | shares (2,417,769)  
Unvested options forfeited (in shares) | shares (25,839)  
Vested options expired (in shares) | shares (68,991)  
Outstanding, end of period (in shares) | shares 10,040,009  
Vested at end of period (in shares) | shares 9,976,636  
Exercisable options, vested and expected to vest (in shares) | shares 10,043,166  
Weighted-Average Exercise Price [Roll forward]    
Outstanding, weighted average exercise price, beginning of period (in dollars per share) $ 3.61  
Granted, weighted average exercise price (in dollars per share) 0.00  
Exercised, weighted average exercise price (in dollars per share) 4.80  
Unvested options forfeited, weighted-average exercise price (in dollars per share) 6.54  
Vested options expired, weighted-average exercise price (in dollars per share) 5.79  
Outstanding, weighted average exercise price, end of period (in dollars per share) 3.30  
Vested at end of period, weighted average exercise price (in dollars per share) 3.26  
Vested and expected to vest, weighted average exercise price (in dollars per share) $ 3.30  
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 4 years 7 months 6 days  
Vested at end of period, weighted average remaining contractual term (in years) 4 years 7 months 2 days  
Vested and expected to vest, weighted average remaining contractual term (in years) 4 years 7 months 6 days  
Outstanding, aggregate intrinsic value | $ $ 86,178,050  
Vested at end of period, aggregate intrinsic value | $ 86,042,771  
Vested or expected to vest, aggregate intrinsic value | $ 86,176,954  
Exercised options, intrinsic value | $ $ 17,994,945  
Number of outstanding options (in shares) | shares 10,040,009  
Outstanding Options, weighted average remaining contractual term (in years) 4 years 7 months 6 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 3.30  
Number of exercisable options (in shares) | shares 9,976,636  
Exercisable Options, weighted average exercise price (in dollars per share) $ 3.26  
Total unrecognized compensation expense | $ $ 98,900  
$0.70 - $1.09    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 2 years 9 months 18 days  
Exercise Price Range, lower range limit (in dollars per share) $ 0.70  
Exercise Price Range, upper range limit (in dollars per share) $ 1.09  
Number of outstanding options (in shares) | shares 1,094,429  
Outstanding Options, weighted average remaining contractual term (in years) 2 years 9 months 18 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 0.91  
Number of exercisable options (in shares) | shares 1,094,429  
Exercisable Options, weighted average exercise price (in dollars per share) $ 0.91  
$1.10 - $1.65    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 3 years 8 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 1.10  
Exercise Price Range, upper range limit (in dollars per share) $ 1.65  
Number of outstanding options (in shares) | shares 4,290,379  
Outstanding Options, weighted average remaining contractual term (in years) 3 years 8 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.30  
Number of exercisable options (in shares) | shares 4,290,379  
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.30  
$2.45 - $3.75    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 5 years  
Exercise Price Range, lower range limit (in dollars per share) $ 2.45  
Exercise Price Range, upper range limit (in dollars per share) $ 3.75  
Number of outstanding options (in shares) | shares 854,001  
Outstanding Options, weighted average remaining contractual term (in years) 5 years  
Outstanding Options, weighted average exercise price (in dollars per share) $ 2.77  
Number of exercisable options (in shares) | shares 854,001  
Exercisable Options, weighted average exercise price (in dollars per share) $ 2.77  
$4.19 - $6.38    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 5 years 8 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 4.19  
Exercise Price Range, upper range limit (in dollars per share) $ 6.38  
Number of outstanding options (in shares) | shares 1,989,205  
Outstanding Options, weighted average remaining contractual term (in years) 5 years 8 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 5.36  
Number of exercisable options (in shares) | shares 1,989,205  
Exercisable Options, weighted average exercise price (in dollars per share) $ 5.36  
$6.49 - $9.78    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 6 years 4 months 24 days  
Exercise Price Range, lower range limit (in dollars per share) $ 6.49  
Exercise Price Range, upper range limit (in dollars per share) $ 9.78  
Number of outstanding options (in shares) | shares 1,713,328  
Outstanding Options, weighted average remaining contractual term (in years) 6 years 4 months 24 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 7.30  
Number of exercisable options (in shares) | shares 1,683,625  
Exercisable Options, weighted average exercise price (in dollars per share) $ 7.26  
$9.90 - $10.99    
Stock options, additional disclosures [Abstract]    
Outstanding Options, weighted average remaining contractual term (in years) 7 years 2 months 12 days  
Exercise Price Range, lower range limit (in dollars per share) $ 9.90  
Exercise Price Range, upper range limit (in dollars per share) $ 10.99  
Number of outstanding options (in shares) | shares 98,667  
Outstanding Options, weighted average remaining contractual term (in years) 7 years 2 months 12 days  
Outstanding Options, weighted average exercise price (in dollars per share) $ 10.38  
Number of exercisable options (in shares) | shares 64,997  
Exercisable Options, weighted average exercise price (in dollars per share) $ 10.38  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity - Restricted Stock Awards (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares issued for services performed (in shares)     17,539 43,344    
Shares issued for services performed     $ 166,000 $ 346,000    
Share-based Compensation [Abstract]            
Share-based compensation expense $ 5,306,000 $ 4,701,000 15,232,000 13,826,000    
Cost of sales            
Share-based Compensation [Abstract]            
Share-based compensation expense 119,000 109,000 393,000 300,000    
Research and development            
Share-based Compensation [Abstract]            
Share-based compensation expense 148,000 159,000 425,000 520,000    
Selling, general and administrative            
Share-based Compensation [Abstract]            
Share-based compensation expense $ 5,039,000 $ 4,433,000 $ 14,414,000 $ 13,006,000    
Restricted stock awards            
Number of Shares            
Unvested, Beginning Balance (in shares)     3,828,445      
Granted (in shares)     3,041,078      
Vested (in shares)     (1,457,449)      
Forfeited (in shares)     (283,198)      
Unvested, Ending Balance (in shares) 5,128,876   5,128,876      
Weighted- Average Grant Date Fair Value            
Unvested, Beginning Balance (in dollars per share) $ 8.97   $ 8.97   $ 8.97 $ 8.53
Granted (in dollars per share)     9.23      
Vested (in dollars per share)     8.42      
Forfeited (in dollars per share)     8.67      
Unvested, Ending Balance (in dollars per share) $ 8.97   $ 8.97      
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock         $ 32,910,620  
Expenses expected to be recognized over a weighted-average period (in years)     2 years 15 days      
Common Stock | Consultant            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares issued for services performed (in shares)     17,539      
Shares issued for services performed     $ 166,000      
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity - Treasury Stock (Details) - USD ($)
 9 Months Ended
Sep. 30, 2017
Oct. 26, 2017
May 12, 2014
Equity, Class of Treasury Stock [Line Items]      
Authorized share amount for repurchase (up to)     $ 10,000,000
Shares repurchased, value $ 43,923,000    
Brokerage commissions 109,000    
Remaining authorizations under the repurchase program $ 13,000    
Shares reissued from the treasury (in shares) 2,684,270    
Shares reissued from the treasury, value $ 24,801,000    
Treasury Stock      
Equity, Class of Treasury Stock [Line Items]      
Share repurchase (in shares) 3,644,327    
Shares repurchased for tax withholding (in shares) 358,861    
Subsequent Event      
Equity, Class of Treasury Stock [Line Items]      
Authorized share amount for repurchase (up to)   $ 120,000,000  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2017
Income Tax Contingency [Line Items]          
Effective tax rate (33.50%)   (14.00%)    
Effective income tax rate reconciliation, excess tax benefit $ 1,702 $ 1,510 $ 5,618 $ 4,205  
Forecast          
Income Tax Contingency [Line Items]          
Effective tax rate         35.10%
Stability Biologics, LLC          
Income Tax Contingency [Line Items]          
Effective income tax rate reconciliation, discrete items related to divestiture $ 5,737   $ 5,737    
Effective tax rate, related to divestiture 15.40% 28.10% 9.40% 31.50%  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Supplemental disclosure of cash flow and non-cash investing and financing activities [Abstract]    
Cash paid for interest $ 119 $ 118
Income taxes paid 8,289 637
Share issuance of 441,009 shares in connection with acquisition 0 3,346
Share issuances of 17,539 and 43,344 shares in exchange for services performed, respectively $ 166 $ 346
Shares issued in connection with business combination (in shares)   441,009
Shares issued for services performed (in shares) 17,539 43,344
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2017
claim
Aug. 18, 2015
claim
Jul. 10, 2015
claim
Jun. 29, 2015
claim
Loss Contingencies [Line Items]                
Lease expiration period     6 years          
Rent expense | $ $ 403 $ 453 $ 1,244 $ 1,311        
Pending Litigation                
Loss Contingencies [Line Items]                
Number of patent challenged grounds (claim)         4      
Pending Litigation | Bone Bank Action                
Loss Contingencies [Line Items]                
Number of patent challenged grounds (claim)             5 7
Opinion allowing a review of patent (claim)             2  
Pending Litigation | Liventa Action, 701 Patent                
Loss Contingencies [Line Items]                
Number of patent challenged grounds (claim)           6    
Pending Litigation | Liventa Action, 437 Patent                
Loss Contingencies [Line Items]                
Number of patent challenged grounds (claim)           7    
Opinion allowing a review of patent (claim)           1    
Standby Letters of Credit                
Loss Contingencies [Line Items]                
Standby letters of credit | $ $ 52   $ 52          
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details)
$ in Thousands
Sep. 30, 2017
USD ($)
Estimated annual lease, royalty, and employment agreement expenses [Abstract]  
2018 $ 2,634
2019 2,826
2020 1,707
2021 1,428
2022 1,470
Thereafter 495
Total Contractual commitments $ 10,560
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Allowance for doubtful accounts        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period $ 7,219 $ 4,086 $ 4,842 $ 3,270
Additions charged to Expense or Revenue 150 800 2,600 1,635
Deductions and write-offs (409) (536) (482) (555)
Balance at End of Period 6,960 4,350 6,960 4,350
Allowance for sales returns, discounts and allowances        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 3,461 2,191 4,894 1,262
Additions charged to Expense or Revenue 1,288 2,591 5,794 5,917
Deductions and write-offs (1,270) (2,520) (7,209) (4,917)
Balance at End of Period 3,479 2,262 3,479 2,262
Allowance for obsolescence        
Movement in Valuation Allowances and Reserves [Roll Forward]        
Balance at Beginning of Period 1,113 1,780 828 397
Additions charged to Expense or Revenue 212 339 953 1,910
Deductions and write-offs (336) (1,411) (792) (1,599)
Balance at End of Period $ 989 $ 708 $ 989 $ 708
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 61 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 150 265 1 false 52 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://mimedx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://mimedx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://mimedx.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2104100 - Disclosure - Divestiture of Stability Biologics, LLC Sheet http://mimedx.com/role/DivestitureOfStabilityBiologicsLlc Divestiture of Stability Biologics, LLC Notes 9 false false R10.htm 2106100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 10 false false R11.htm 2107100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 2108100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 12 false false R13.htm 2109100 - Disclosure - Credit Facility Sheet http://mimedx.com/role/CreditFacility Credit Facility Notes 13 false false R14.htm 2110100 - Disclosure - Net Income Per Share Sheet http://mimedx.com/role/NetIncomePerShare Net Income Per Share Notes 14 false false R15.htm 2111100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 15 false false R16.htm 2112100 - Disclosure - Income Taxes Sheet http://mimedx.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2114100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Notes 17 false false R18.htm 2115100 - Disclosure - Contractual Commitments and Contingencies Sheet http://mimedx.com/role/ContractualCommitmentsAndContingencies Contractual Commitments and Contingencies Notes 18 false false R19.htm 2117100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 19 false false R20.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 20 false false R21.htm 2304301 - Disclosure - Divestiture of Stability Biologics, LLC (Tables) Sheet http://mimedx.com/role/DivestitureOfStabilityBiologicsLlcTables Divestiture of Stability Biologics, LLC (Tables) Uncategorized 21 false false R22.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 22 false false R23.htm 2307301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 23 false false R24.htm 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 24 false false R25.htm 2310301 - Disclosure - Net Income Per Share (Tables) Sheet http://mimedx.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Uncategorized 25 false false R26.htm 2311301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 26 false false R27.htm 2314301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Uncategorized 27 false false R28.htm 2315301 - Disclosure - Contractual Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesTables Contractual Commitments and Contingencies (Tables) Uncategorized 28 false false R29.htm 2401401 - Disclosure - Basis of Presentation (Details) Sheet http://mimedx.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Uncategorized 29 false false R30.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 30 false false R31.htm 2404402 - Disclosure - Divestiture of Stability Biologics, LLC - Summary of Assets Transferred and Consideration Received (Details) Sheet http://mimedx.com/role/DivestitureOfStabilityBiologicsLlcSummaryOfAssetsTransferredAndConsiderationReceivedDetails Divestiture of Stability Biologics, LLC - Summary of Assets Transferred and Consideration Received (Details) Uncategorized 31 false false R32.htm 2404403 - Disclosure - Divestiture of Stability Biologics, LLC - Narrative (Details) Sheet http://mimedx.com/role/DivestitureOfStabilityBiologicsLlcNarrativeDetails Divestiture of Stability Biologics, LLC - Narrative (Details) Uncategorized 32 false false R33.htm 2406402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 33 false false R34.htm 2407402 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Uncategorized 34 false false R35.htm 2407403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Uncategorized 35 false false R36.htm 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementSummaryOfIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Summary of Intangible Assets (Details) Uncategorized 36 false false R37.htm 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementNarrativeDetails Intangible Assets and Royalty Agreement - Narrative (Details) Uncategorized 37 false false R38.htm 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Estimated Future Amortization Expense for Intangible Assets (Details) Uncategorized 38 false false R39.htm 2409401 - Disclosure - Credit Facility (Details) Sheet http://mimedx.com/role/CreditFacilityDetails Credit Facility (Details) Uncategorized 39 false false R40.htm 2410402 - Disclosure - Net Income Per Share (Details) Sheet http://mimedx.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Uncategorized 40 false false R41.htm 2411402 - Disclosure - Equity - Stock Incentive Plans (Details) Sheet http://mimedx.com/role/EquityStockIncentivePlansDetails Equity - Stock Incentive Plans (Details) Uncategorized 41 false false R42.htm 2411403 - Disclosure - Equity - Restricted Stock Awards (Details) Sheet http://mimedx.com/role/EquityRestrictedStockAwardsDetails Equity - Restricted Stock Awards (Details) Uncategorized 42 false false R43.htm 2411404 - Disclosure - Equity - Treasury Stock (Details) Sheet http://mimedx.com/role/EquityTreasuryStockDetails Equity - Treasury Stock (Details) Uncategorized 43 false false R44.htm 2412401 - Disclosure - Income Taxes (Details) Sheet http://mimedx.com/role/IncomeTaxesDetails Income Taxes (Details) Uncategorized 44 false false R45.htm 2414402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Uncategorized 45 false false R46.htm 2415402 - Disclosure - Contractual Commitments and Contingencies - Narrative (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesNarrativeDetails Contractual Commitments and Contingencies - Narrative (Details) Uncategorized 46 false false R47.htm 2415403 - Disclosure - Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Sheet http://mimedx.com/role/ContractualCommitmentsAndContingenciesEstimatedAnnualLeasePaymentsDetails Contractual Commitments and Contingencies - Estimated Annual Lease Payments (Details) Uncategorized 47 false false R48.htm 2417401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 48 false false All Reports Book All Reports mdxg-20170930.xml mdxg-20170930.xsd mdxg-20170930_cal.xml mdxg-20170930_def.xml mdxg-20170930_lab.xml mdxg-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 66 0001376339-17-000138-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-17-000138-xbrl.zip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